Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (ALTTO)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Breast International Group
Canadian Cancer Trials Group
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00490139
First received: June 20, 2007
Last updated: April 3, 2016
Last verified: April 2016
  Purpose

This is a randomised, open label multi-centre phase III study comparing the activity of lapatinib alone versus trastuzumab alone versus trastuzumab followed by lapatinib versus lapatinib concomitantly with trastuzumab in the adjuvant treatment of patients with ErbB2 overexpressing and/or amplified breast cancer. Patients will be enrolled according to one of two design schemas, with Design 2 having two chemotherapy options (Design 2 and 2B), and will be randomised to one of four treatment regimens within each design schema.

The primary objective of this study is to compare disease-free survival (DFS) in patients with HER2 overexpressing and/or amplified breast cancer randomised to trastuzumab for one year versus lapatinib for one year versus trastuzumab (12 or 18 weeks, according to assigned design) followed by a six-week treatment-free interval followed by lapatinib (28 or 34 weeks, according to assigned design) versus trastuzumab in combination with lapatinib for one year (52 weeks). Secondary objectives include treatment comparisons with respect to overall survival, time to recurrence, time to distant recurrence, safety and tolerability, incidence of brain metastasis, and analyses conducted separately for cohorts of patients defined by presence or absence of cMyc oncogene amplification, expression level of PTEN and presence or absence of the p95HER2 receptor. On August 18, 2011, the ALTTO Independent Data Monitoring Committee (IDMC) met to review the first planned interim analysis. The IDMC reported that the comparison of lapatinib alone versus trastuzumab alone crossed the futility boundary, indicating that the lapatinib alone arm was unlikely to meet the pre-specified criteria to demonstrate non-inferiority to trastuzumab alone with respect to disease-free survival (DFS). The IDMC also stated that the other three arms (trastuzumab alone, sequential trastuzumab/lapatinib arm and the combination arm) should continue as planned with no changes.


Condition Intervention Phase
Neoplasms, Breast
Drug: Lapatinib
Biological: Trastuzumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Disease-free Survival (DFS) [ Time Frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years) ] [ Designated as safety issue: No ]
    Disease-free survival is defined as the interval between randomization and the date of the first occurence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer (SPC), or death from any cause. DFS was estimated using the Kaplan Meier method.The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who had disease free survival for the indicated years.


Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: From randomization until death due to any cause (median follow-up of 4.5 years) ] [ Designated as safety issue: No ]
    Overall survival is defined as the time from randomization until death due to any cause. Overall survival was calculated in years as (date of death minus the date of randomization +1) divided by 365.25. The percentile data values presented here indicate the percentage (99, 98, 97, 96, 95 and 90 percent) of participants who survived for the indicated years.

  • Time to Recurrence [ Time Frame: From randomization until the date of the first occurrence of a disease recurrence (median follow-up of 4.5 years) ] [ Designated as safety issue: No ]
    Time to recurrence is defined as the interval between the date of randomization and the date of the first occurrence of a disease recurrence (local, regional or distant). The percentile data values presented here indicate the percentage (95, 90, 85, and 80 percent) of participants who did not have disease recurrence for the indicated years. IDMC=Independent Data Monitoring Committee.

  • Time to Distant Recurrence [ Time Frame: From randomization until the date of the first occurrence of distant recurrence (median follow-up of 4.5 years) ] [ Designated as safety issue: No ]
    Time to distant recurrence is defined as the interval between the date of randomization and the date of the first occurrence of distant recurrence (including central nervous system recurrence). The percentile data values presented here indicate the percentage (95, 90, 85 and 80 percent) of participants who did not have distant recurrence for the indicated years.

  • Time to Central Nervous System Recurrence [ Time Frame: From randomization until the first central nervous system recurrence (median follow-up of 4.5 years) ] [ Designated as safety issue: No ]
    Time to central nervous system recurrence is defined as the time from randomization until the first central nervous system recurrence. Both brain metastasis and meningitis carcinomatosa were considered.The percentile data values presented here indicate that 95 percent of participants did not have central nervous system recurrence for the indicated years.

  • DFS Ignoring Non-breast Second Primary Malignancies [ Time Frame: From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years) ] [ Designated as safety issue: No ]
    Disease-free survival is defined as the interval between randomization and the date of the first occurence of disease recurrence (local, regional or distant), a contralateral invasive breast cancer, a second primary cancer, or death from any cause. DFS was estimated using the Kaplan Meier method. The non-breast second primary malignancies were not considered events.The percentile data values presented here indicate the percentage (95, 90, 85, 80 and 75 percent) of participants who did not have DFS ignoring non-breast second primary malignancies for the indicated years. Zero participants were analyzed in the lapatinib arm, as the IDMC discontinued the lapatinib-alone arm due to futility at the time of the first interim analysis (lapatinib participants were then offered trastuzumab).


Enrollment: 8381
Study Start Date: May 2007
Estimated Study Completion Date: November 2022
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1: Trastuzumab

Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.

Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).

Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total).

Biological: Trastuzumab
Antibody
Experimental: Arm 2: Lapatinib

Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.

Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.

Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).

Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total).

Drug: Lapatinib
Small molecule inhibitor
Experimental: Arm 3: Trastuzumab followed by Lapatinib

Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).

Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).

Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total).

Biological: Trastuzumab
Antibody
Experimental: Arm 4: Lapatinib in combination with Trastuzumab

Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).

Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).

Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total).

Drug: Lapatinib
Small molecule inhibitor
Biological: Trastuzumab
Antibody

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;
  • Non-metastatic operable primary invasive adenocarcinoma of the breast fulfilling the following:

    1. Histologically confirmed
    2. Adequately excised (exceptions: patients who have 'non-resectable' deep margin invasion are eligible provided they have had or will receive radiotherapy encompassing the region concerned; patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumour bed);
    3. Axilla dissected; sentinel node sampling is allowed provided that axillary dissection follows confirmation of a positive sentinel node; sentinel node sampling alone is NOT acceptable after neoadjuvant chemotherapy (in patients receiving neoadjuvant chemotherapy lymph node status will be considered unknown, regardless of the results of post-chemotherapy axillary dissection);
    4. Axillary node positive patient OR node negative patient with a tumour greater than or equal to 1.0 cm in greatest diameter. For clarification, isolated tumour cells (ITC) are considered pN0 and micrometastases are considered pN1
  • Known hormone receptor status (ER/PgR or ER alone)
  • For Designs 1 and 2: Patients must have received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen or listed as an exception in Table 5 of the protocol.

For Design 1: Randomization must be performed no longer than 12 weeks from day 1 of the last chemotherapy cycle after obtaining a post-chemotherapy LVEF ≥ 50. Study treatment must start no more than 14 days after randomization For Design 2: Randomization must be performed no longer than 6 weeks from day 1 of the last anthracycline-containing chemotherapy cycle after obtaining a post-anthracycline chemotherapy LVEF ≥ 50. Study treatment must start no more than 14 days after randomization and must be concurrent with taxanes.

For Design 2B: Randomisation must be performed no longer than 8 weeks from definitive surgery. Non-anthracycline platinum containing regimen (docetaxel and carboplatin) and study treatment must start concomitantly and no more than 14 days after randomisation.

  • Baseline LVEF ≥50% measured by echocardiography or MUGA scan. For Design 1 and Design 2 - after completion of all anthracycline-based (neo-) adjuvant chemotherapy and prior to the targeted therapy(ies); for Design 2B - prior to targeted therapy(ies) and chemotherapy (docetaxel and carboplatin)
  • Over expression and/or amplification of HER2 in the invasive component of the primary tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should be collected before neoadjuvant treatment starts), according to one of the following definitions [Wolff et al 2007] and confirmed by central laboratory prior to randomization:
  • 3+ over expression by IHC (> 30% of invasive tumour cells);
  • 2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification;
  • HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a negative or equivocal overall result (FISH test ratio of ≤ 2.2, ≤ 6.0 HER2 gene copies per nucleus) and staining scores of 0, 1+, 2+ or 3+ (in 30% or less neoplastic cells) by IHC are not eligible for participation in the trial.

Equivocal local results may be submitted for a final determination by the central laboratory.

  • Completion of all necessary baseline laboratory and radiological investigations
  • Signed written informed consent (approved by an Independent Ethics Committee (IEC) and obtained prior to any study specific screening procedures).

Exclusion Criteria:

  • History of any prior (ipsi- and/or contralateral) invasive breast carcinoma;
  • Past (less than 10 years) or current history of malignant neoplasms, except for curatively treated 1) basal and squamous cell carcinoma of the skin or 2) carcinoma in situ of the cervix.

NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy (chemotherapy or endocrine) are eligible for the study. Patients with any prior diagnosis of breast cancer or melanoma, at any time, are excluded from this study.

  • Any clinically staged T4 tumour, including inflammatory breast cancer;
  • Bilateral tumours;
  • This exclusion criterion has been removed as of protocol amendment 1.

NOTE: multifocal/multicentric tumours are permitted:

  • If the patient is node-negative: one of the lesions must be equal or greater than 1.0 cm (sum of the lesion diameters is not acceptable) AND must have positive HER2 status centrally-confirmed;
  • If patient is node-positive: lesion size does not matter BUT one of the lesions must have HER2 positivity centrally-confirmed. If several lesions are found to be HER2 positive locally, the largest lesion should be considered for central review.
  • Maximum cumulative dose of doxorubicin >360mg/m² or maximum cumulative dose of epirubicin >720mg/m² or any prior anthracyclines unrelated to the present breast cancer;
  • (Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support;
  • Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer;
  • Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or will not be irradiated, or patients with supraclavicular lymph node involvement (confirmed by fine needle aspirate or biopsy);
  • Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for breast cancer;
  • Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the present breast cancer;
  • Concurrent anti-cancer treatment in another investigational trial with hormone therapy or immunotherapy unless approved by the Executive Committee:
  • Serious cardiac illness or medical conditions including but not confined to:

History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <50%); High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled); Angina pectoris requiring antianginal medication; Clinically significant valvular heart disease; Evidence of transmural infarction on ECG; Poorly controlled hypertension (e.g. systolic >180mm Hg or diastolic >100mm Hg);

  • Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness;
  • Any of the following abnormal laboratory tests immediately prior to randomization:

serum total bilirubin >1.5 x upper limit of normal (ULN), in the case of known Gilbert's syndrome, a higher serum total bilirubin (<2 X ULN) is allowed; alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) >2.5 x ULN; alkaline phosphatase (ALP) > 2.5 x ULN; serum creatinine >2.0 x ULN; total white blood cell count (WBC) <2.5 x 10^9/L; absolute neutrophil count <1.5 x 10^9/L; platelets <100 x 10^9/L.

  • Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy;
  • Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication. Subjects with ulcerative colitis are also excluded;
  • Pregnant, lactating or women of childbearing potential without a negative pregnancy test - urine or serum - within 7 days prior to randomization, irrespective of the method of contraception used, including tubal ligation;
  • Women of childbearing potential and male participants with partners of child bearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment (adequate contraceptive measures: intra-uterine device, barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not indicated in this patient population);
  • Concomitant use of CYP3A4 inhibitors or inducers.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00490139

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Mobile, Alabama, United States, 36608
United States, Alaska
Novartis Investigative Site
Anchorage, Alaska, United States, 99508
Novartis Investigative Site
Fairbanks, Alaska, United States, 99701
United States, Arizona
Novartis Investigative Site
Phoenix, Arizona, United States, 85012
Novartis Investigative Site
Scottsdale, Arizona, United States, 85259
Novartis Investigative Site
Tucson, Arizona, United States, 85704
Novartis Investigative Site
Tucson, Arizona, United States, 85715
United States, Arkansas
Novartis Investigative Site
Jonesboro, Arkansas, United States, 72401
United States, California
Novartis Investigative Site
Berkeley, California, United States, 94705
Novartis Investigative Site
Burlingame, California, United States, 94010
Novartis Investigative Site
Castro Valley, California, United States, 94546
Novartis Investigative Site
Duarte, California, United States, 91010
Novartis Investigative Site
Fairfield, California, United States, 94533
Novartis Investigative Site
Fremont, California, United States, 94538
Novartis Investigative Site
Fresno, California, United States, 93720
Novartis Investigative Site
Glendale, California, United States, 91204
Novartis Investigative Site
Greenbrae, California, United States, 94904
Novartis Investigative Site
La Jolla, California, United States, 92093-0987
Novartis Investigative Site
La Jolla, California, United States, 92093
Novartis Investigative Site
Loma Linda, California, United States, 92534
Novartis Investigative Site
Martinez, California, United States, 94553-3156
Novartis Investigative Site
Marysville, California, United States, 95901
Novartis Investigative Site
Monterey, California, United States, 93940
Novartis Investigative Site
Mountain View, California, United States, 94040
Novartis Investigative Site
Murrieta, California, United States, 92562
Novartis Investigative Site
Oakland, California, United States, 94602
Novartis Investigative Site
Oakland, California, United States, 94609
Novartis Investigative Site
Orange, California, United States, 92868
Novartis Investigative Site
Palm Springs, California, United States, 92262
Novartis Investigative Site
Palo Alto, California, United States, 94301
Novartis Investigative Site
Pismo Beach, California, United States, 93449
Novartis Investigative Site
Pleasanton, California, United States, 94588
Novartis Investigative Site
Sacramento, California, United States, 95817
Novartis Investigative Site
San Francisco, California, United States, 94110
Novartis Investigative Site
San Francisco, California, United States, 94115
Novartis Investigative Site
San Francisco, California, United States, 94118
Novartis Investigative Site
San Leandro, California, United States, 94578
Novartis Investigative Site
Vallejo, California, United States, 94589
United States, Colorado
Novartis Investigative Site
Aurora, Colorado, United States, 80012
Novartis Investigative Site
Boulder, Colorado, United States, 80301
Novartis Investigative Site
Colorado Springs, Colorado, United States, 80907
Novartis Investigative Site
Denver, Colorado, United States, 80204
Novartis Investigative Site
Denver, Colorado, United States, 80210
Novartis Investigative Site
Denver, Colorado, United States, 80217-3364
Novartis Investigative Site
Denver, Colorado, United States, 80218
Novartis Investigative Site
Denver, Colorado, United States, 80220
Novartis Investigative Site
Denver, Colorado, United States, 80224
Novartis Investigative Site
Edwards, Colorado, United States, 81632
Novartis Investigative Site
Englewood, Colorado, United States, 80110
Novartis Investigative Site
Fort Collins, Colorado, United States, 80524
Novartis Investigative Site
Ft. Collins, Colorado, United States, 80528
Novartis Investigative Site
Glenwood Springs, Colorado, United States, 81601
Novartis Investigative Site
Grand Junction, Colorado, United States, 81502
Novartis Investigative Site
Greeley, Colorado, United States, 80631
Novartis Investigative Site
Lone Tree, Colorado, United States, 80124
Novartis Investigative Site
Longmont, Colorado, United States, 80502
Novartis Investigative Site
Loveland, Colorado, United States, 80539
Novartis Investigative Site
Montrose, Colorado, United States, 81401
Novartis Investigative Site
Pueblo, Colorado, United States, 81004
Novartis Investigative Site
Thornton, Colorado, United States, 80229
Novartis Investigative Site
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
Novartis Investigative Site
Hartford, Connecticut, United States, 06105
Novartis Investigative Site
New Haven, Connecticut, United States, 06520
Novartis Investigative Site
Stamford, Connecticut, United States, 06904
Novartis Investigative Site
Torrington, Connecticut, United States, 06790
United States, Delaware
Novartis Investigative Site
Dover, Delaware, United States, 19901
Novartis Investigative Site
Milford, Delaware, United States, 19963
United States, District of Columbia
Novartis Investigative Site
Washington, District of Columbia, United States, 20007
Novartis Investigative Site
Washington, District of Columbia, United States, 20307
United States, Florida
Novartis Investigative Site
Boca Raton, Florida, United States, 33486
Novartis Investigative Site
Fort Fauderdale, Florida, United States, 33308
Novartis Investigative Site
Fort Myers, Florida, United States, 33916
Novartis Investigative Site
Hollywood, Florida, United States, 33021
Novartis Investigative Site
Jacksonville, Florida, United States, 32207
Novartis Investigative Site
Jacksonville, Florida, United States, 32224
Novartis Investigative Site
Jupiter, Florida, United States, 33458
Novartis Investigative Site
Lakeland, Florida, United States, 33805
Novartis Investigative Site
Miami Beach, Florida, United States, 33140
Novartis Investigative Site
New Port Richey, Florida, United States, 34655
Novartis Investigative Site
Ocala, Florida, United States, 34471
Novartis Investigative Site
Orange Park, Florida, United States, 32073
Novartis Investigative Site
Orlando, Florida, United States, 32803
Novartis Investigative Site
Orlando, Florida, United States, 32806
Novartis Investigative Site
Titusville, Florida, United States, 32796
Novartis Investigative Site
Weston, Florida, United States, 33331
United States, Georgia
Novartis Investigative Site
Athens, Georgia, United States, 30607
Novartis Investigative Site
Atlanta, Georgia, United States, 30309
Novartis Investigative Site
Atlanta, Georgia, United States, 30342
Novartis Investigative Site
Augusta, Georgia, United States, 30901
Novartis Investigative Site
Augusta, Georgia, United States, 30912
Novartis Investigative Site
Austell, Georgia, United States, 30106
Novartis Investigative Site
Columbus, Georgia, United States, 31904
Novartis Investigative Site
Decatur, Georgia, United States, 30033
Novartis Investigative Site
Fort Gordon, Georgia, United States, 30905-5650
Novartis Investigative Site
Gainesville, Georgia, United States, 30501
Novartis Investigative Site
Lawrenceville, Georgia, United States, 30045
Novartis Investigative Site
Marietta, Georgia, United States, 30060
Novartis Investigative Site
Riverdale, Georgia, United States, 30274
Novartis Investigative Site
Rome, Georgia, United States, 30165
Novartis Investigative Site
Savannah, Georgia, United States, 31405
Novartis Investigative Site
Valdosta, Georgia, United States, 31603
United States, Hawaii
Novartis Investigative Site
Aiea, Hawaii, United States, 96701
Novartis Investigative Site
Honolulu, Hawaii, United States, 96813
Novartis Investigative Site
Honolulu, Hawaii, United States, 96817
Novartis Investigative Site
Honolulu, Hawaii, United States, 96826
Novartis Investigative Site
Honolulu, Hawaii, United States, 96859
Novartis Investigative Site
Lihue, Hawaii, United States, 96766
Novartis Investigative Site
Wailuku, Hawaii, United States, 96793
United States, Idaho
Novartis Investigative Site
Boise, Idaho, United States, 83706
Novartis Investigative Site
Boise, Idaho, United States, 83712
United States, Illinois
Novartis Investigative Site
Alton, Illinois, United States, 62002
Novartis Investigative Site
Aurora, Illinois, United States, 60504
Novartis Investigative Site
Berwyn, Illinois, United States, 60402
Novartis Investigative Site
Bloomington, Illinois, United States, 61701
Novartis Investigative Site
Canton, Illinois, United States, 61520
Novartis Investigative Site
Carthage, Illinois, United States, 62321
Novartis Investigative Site
Chicago, Illinois, United States, 60611
Novartis Investigative Site
Chicago, Illinois, United States, 60657
Novartis Investigative Site
Eureka, Illinois, United States, 61530
Novartis Investigative Site
Evanston, Illinois, United States, 60201
Novartis Investigative Site
Galesburg, Illinois, United States, 61401
Novartis Investigative Site
Harvey, Illinois, United States, 60426
Novartis Investigative Site
Havana, Illinois, United States, 62644
Novartis Investigative Site
Highland Park, Illinois, United States, 60035
Novartis Investigative Site
Hopedale, Illinois, United States, 61747
Novartis Investigative Site
Joliet, Illinois, United States, 60432
Novartis Investigative Site
Joliet, Illinois, United States, 60435
Novartis Investigative Site
Kankakee, Illinois, United States, 60901
Novartis Investigative Site
Kewanee, Illinois, United States, 61443
Novartis Investigative Site
La Grange, Illinois, United States, 60525
Novartis Investigative Site
Libertyville, Illinois, United States, 60048
Novartis Investigative Site
Macomb, Illinois, United States, 61455
Novartis Investigative Site
Maywood, Illinois, United States, 60153
Novartis Investigative Site
Moline, Illinois, United States, 61265
Novartis Investigative Site
Monmouth, Illinois, United States, 61462
Novartis Investigative Site
Mt. Vernon, Illinois, United States, 62864
Novartis Investigative Site
Naperville, Illinois, United States, 60563
Novartis Investigative Site
Niles, Illinois, United States, 60714
Novartis Investigative Site
Normal, Illinois, United States, 61761
Novartis Investigative Site
Oak Lawn, Illinois, United States, 60453-2699
Novartis Investigative Site
Ottawa, Illinois, United States, 61350
Novartis Investigative Site
Park Ridge, Illinois, United States, 60068
Novartis Investigative Site
Pekin, Illinois, United States, 61554
Novartis Investigative Site
Pekin, Illinois, United States, 61603
Novartis Investigative Site
Peoria, Illinois, United States, 61603
Novartis Investigative Site
Peoria, Illinois, United States, 61614
Novartis Investigative Site
Peoria, Illinois, United States, 61615
Novartis Investigative Site
Peoria, Illinois, United States, 61637
Novartis Investigative Site
Peru, Illinois, United States, 61354
Novartis Investigative Site
Princeton, Illinois, United States, 61356
Novartis Investigative Site
Rockford, Illinois, United States, 61104
Novartis Investigative Site
Skokie, Illinois, United States, 60077
Novartis Investigative Site
Spring Valley, Illinois, United States, 61362
Novartis Investigative Site
Springfield, Illinois, United States, 62781-0001
Novartis Investigative Site
Urbana, Illinois, United States, 61801
Novartis Investigative Site
Warrenville, Illinois, United States, 60555
Novartis Investigative Site
Winfield, Illinois, United States, 60190
United States, Indiana
Novartis Investigative Site
Beech Grove, Indiana, United States, 46107
Novartis Investigative Site
Elkhart, Indiana, United States, 46515
Novartis Investigative Site
Fort Wayne, Indiana, United States, 46815
Novartis Investigative Site
Indianapolis, Indiana, United States, 46202
Novartis Investigative Site
Indianapolis, Indiana, United States, 46260
Novartis Investigative Site
Kokomo, Indiana, United States, 46904
Novartis Investigative Site
La Porte, Indiana, United States, 46350
Novartis Investigative Site
Michigan city, Indiana, United States, 46360
Novartis Investigative Site
Muncie, Indiana, United States, 47303
Novartis Investigative Site
Richmond, Indiana, United States, 47374
Novartis Investigative Site
South Bend, Indiana, United States, 46601
Novartis Investigative Site
South Bend, Indiana, United States, 46617
United States, Iowa
Novartis Investigative Site
Ames, Iowa, United States, 50010
Novartis Investigative Site
Bettendorf, Iowa, United States, 52722
Novartis Investigative Site
Cedar Rapids, Iowa, United States, 52402
Novartis Investigative Site
Cedar Rapids, Iowa, United States, 52403
Novartis Investigative Site
Des Moines, Iowa, United States, 50307
Novartis Investigative Site
Des Moines, Iowa, United States, 50309
Novartis Investigative Site
Des Moines, Iowa, United States, 50314
Novartis Investigative Site
Des Moines, Iowa, United States, 50316
Novartis Investigative Site
Mason City, Iowa, United States
Novartis Investigative Site
Ottumwa, Iowa, United States, 52501
Novartis Investigative Site
Sioux City, Iowa, United States, 51101-1733
Novartis Investigative Site
Sioux City, Iowa, United States, 51104
Novartis Investigative Site
Waterloo, Iowa, United States, 50701
Novartis Investigative Site
Waterloo, Iowa, United States, 50702
United States, Kansas
Novartis Investigative Site
Anthony, Kansas, United States, 67003
Novartis Investigative Site
Chanute, Kansas, United States, 66720
Novartis Investigative Site
Dodge City, Kansas, United States, 67801
Novartis Investigative Site
El Dorado, Kansas, United States, 67042
Novartis Investigative Site
Fort Scott, Kansas, United States, 66701
Novartis Investigative Site
Independence, Kansas, United States, 67301
Novartis Investigative Site
Kansas City, Kansas, United States, 66160
Novartis Investigative Site
Kingman, Kansas, United States, 67068
Novartis Investigative Site
Lawrence, Kansas, United States, 66044
Novartis Investigative Site
Liberal, Kansas, United States, 67901
Novartis Investigative Site
Newton, Kansas, United States, 67114
Novartis Investigative Site
Olathe, Kansas, United States, 66061
Novartis Investigative Site
Overland Park, Kansas, United States, 66209
Novartis Investigative Site
Overland Park, Kansas, United States, 66210
Novartis Investigative Site
Overland Park, Kansas, United States, 66213
Novartis Investigative Site
Parsons, Kansas, United States, 67357
Novartis Investigative Site
Prairie Village, Kansas, United States, 66208
Novartis Investigative Site
Pratt, Kansas, United States, 67124
Novartis Investigative Site
Salina, Kansas, United States, 67042
Novartis Investigative Site
Shawnee Mission, Kansas, United States, 66204
Novartis Investigative Site
Topeka, Kansas, United States, 66604
Novartis Investigative Site
Topeka, Kansas, United States, 66606
Novartis Investigative Site
Wellington, Kansas, United States, 67152
Novartis Investigative Site
Wichita, Kansas, United States, 67203
Novartis Investigative Site
Wichita, Kansas, United States, 67208
Novartis Investigative Site
Wichita, Kansas, United States, 67214
Novartis Investigative Site
Winfield, Kansas, United States, 67156
United States, Kentucky
Novartis Investigative Site
Louisville, Kentucky, United States, 40292
United States, Louisiana
Novartis Investigative Site
Baton Rouge, Louisiana, United States, 70806
Novartis Investigative Site
Baton Rouge, Louisiana, United States, 70809
Novartis Investigative Site
Houma, Louisiana, United States, 70360
Novartis Investigative Site
New Orleans, Louisiana, United States, 70112
Novartis Investigative Site
New Orleans, Louisiana, United States, 70121
United States, Maine
Novartis Investigative Site
Portland, Maine, United States, 04101
Novartis Investigative Site
Scarborough, Maine, United States, 04074
United States, Maryland
Novartis Investigative Site
Baltimore, Maryland, United States, 21201
Novartis Investigative Site
Baltimore, Maryland, United States, 21287-8936
Novartis Investigative Site
Bethesda, Maryland, United States, 20889-5600
Novartis Investigative Site
Easton, Maryland, United States, 21601
Novartis Investigative Site
Frederick, Maryland, United States, 21701
Novartis Investigative Site
Hagerstown, Maryland, United States, 21740
Novartis Investigative Site
Silver Spring, Maryland, United States, 20910
Novartis Investigative Site
Towson, Maryland, United States, 21204
Novartis Investigative Site
Westminster, Maryland, United States, 21157
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02114
Novartis Investigative Site
Boston, Massachusetts, United States, 02115
Novartis Investigative Site
Boston, Massachusetts, United States, 02135
Novartis Investigative Site
Boston, Massachusetts, United States, 02215
Novartis Investigative Site
Burlington, Massachusetts, United States, 01805
Novartis Investigative Site
Gloucester, Massachusetts, United States, 01930
Novartis Investigative Site
Hyannis, Massachusetts, United States, 02601
Novartis Investigative Site
Lowell, Massachusetts, United States
Novartis Investigative Site
Peabody, Massachusetts, United States, 01960
United States, Michigan
Novartis Investigative Site
Adrian, Michigan, United States, 49221
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48106-0995
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48106
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48109
Novartis Investigative Site
Battle Creek, Michigan, United States, 49016
Novartis Investigative Site
Big Rapids, Michigan, United States
Novartis Investigative Site
Byron Center, Michigan, United States, 49519
Novartis Investigative Site
Dearborn, Michigan, United States, 48123
Novartis Investigative Site
Detroit, Michigan, United States, 48202
Novartis Investigative Site
Detroit, Michigan, United States, 48236
Novartis Investigative Site
Escanaba, Michigan, United States, 49431
Novartis Investigative Site
Flint, Michigan, United States, 48502
Novartis Investigative Site
Flint, Michigan, United States, 48532
Novartis Investigative Site
Grand Rapids, Michigan, United States, 49503
Novartis Investigative Site
Iron Mountain, Michigan, United States, 49801
Novartis Investigative Site
Jackson, Michigan, United States, 49201
Novartis Investigative Site
Kalamazoo, Michigan, United States, 49001
Novartis Investigative Site
Kalamazoo, Michigan, United States, 49007
Novartis Investigative Site
Lansing, Michigan, United States, 48912
Novartis Investigative Site
Livonia, Michigan, United States, 48154
Novartis Investigative Site
Monroe, Michigan, United States, 48162
Novartis Investigative Site
Muskegon, Michigan, United States, 49444
Novartis Investigative Site
Pontiac, Michigan, United States, 48341-2985
Novartis Investigative Site
Port Huron, Michigan, United States, 48060
Novartis Investigative Site
Saginaw, Michigan, United States, 48601
Novartis Investigative Site
Southfield, Michigan, United States, 48075
Novartis Investigative Site
St. Joseph, Michigan, United States, 49085
Novartis Investigative Site
St. Joseph, Michigan, United States
Novartis Investigative Site
Traverse City, Michigan, United States, 49684
Novartis Investigative Site
Warren, Michigan, United States, 48093
United States, Minnesota
Novartis Investigative Site
Albert Lea, Minnesota, United States, 56007
Novartis Investigative Site
Alexandria, Minnesota, United States, 56308
Novartis Investigative Site
Bemidhi, Minnesota, United States, 56601
Novartis Investigative Site
Burnsville, Minnesota, United States, 55337
Novartis Investigative Site
Coon Rapids, Minnesota, United States, 55433
Novartis Investigative Site
Duluth, Minnesota, United States, 55805
Novartis Investigative Site
Edina, Minnesota, United States, 55435
Novartis Investigative Site
Fergus Falls, Minnesota, United States, 56537
Novartis Investigative Site
Fridley, Minnesota, United States, 55432
Novartis Investigative Site
Hutchinson, Minnesota, United States, 55350
Novartis Investigative Site
Litchfield, Minnesota, United States, 55355
Novartis Investigative Site
Mankato, Minnesota, United States, 56002
Novartis Investigative Site
Maplewood, Minnesota, United States, 55109
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55407-3799
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55415
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55455
Novartis Investigative Site
Robbinsdale, Minnesota, United States, 55422
Novartis Investigative Site
Rochester, Minnesota, United States, 55905
Novartis Investigative Site
Saint Cloud, Minnesota, United States, 56303
Novartis Investigative Site
Saint Paul, Minnesota, United States, 55101
Novartis Investigative Site
Saint Paul, Minnesota, United States, 55102
Novartis Investigative Site
Shakopee, Minnesota, United States, 55379
Novartis Investigative Site
St Paul, Minnesota, United States, 55102
Novartis Investigative Site
St. Louis Park, Minnesota, United States, 55416
Novartis Investigative Site
Waconia, Minnesota, United States, 55387
Novartis Investigative Site
Willmar, Minnesota, United States, 56201
Novartis Investigative Site
Woodbury, Minnesota, United States, 55125
United States, Mississippi
Novartis Investigative Site
Jackson, Mississippi, United States, 39216-4505
Novartis Investigative Site
Keesler AFB, Mississippi, United States, 39534
Novartis Investigative Site
Pascagoula, Mississippi, United States, 39581
United States, Missouri
Novartis Investigative Site
Bolivar, Missouri, United States, 65613
Novartis Investigative Site
Cape Girardeau, Missouri, United States, 63701
Novartis Investigative Site
Cape Girardeau, Missouri, United States, 63703
Novartis Investigative Site
Independence, Missouri, United States, 64050
Novartis Investigative Site
Joplin, Missouri, United States, 64804
Novartis Investigative Site
Kansas City, Missouri, United States, 64108
Novartis Investigative Site
Kansas City, Missouri, United States, 64111
Novartis Investigative Site
Kansas City, Missouri, United States, 64114
Novartis Investigative Site
Kansas City, Missouri, United States, 64116
Novartis Investigative Site
Kansas City, Missouri, United States, 64118
Novartis Investigative Site
Kansas City, Missouri, United States, 64131
Novartis Investigative Site
Kansas City, Missouri, United States, 64132
Novartis Investigative Site
Kansas City, Missouri, United States, 64154
Novartis Investigative Site
Lee's Summit, Missouri, United States, 64086
Novartis Investigative Site
Liberty, Missouri, United States, 64068
Novartis Investigative Site
Saint Joseph, Missouri, United States, 64506
Novartis Investigative Site
Saint Jospeh, Missouri, United States, 64507
Novartis Investigative Site
Saint Louis, Missouri, United States, 63109
Novartis Investigative Site
Saint Louis, Missouri, United States, 63131
Novartis Investigative Site
Springfield, Missouri, United States, 65802
Novartis Investigative Site
Springfield, Missouri, United States, 65804
Novartis Investigative Site
Springfield, Missouri, United States, 65807
Novartis Investigative Site
St Louis, Missouri, United States, 63141
Novartis Investigative Site
St. Louis, Missouri, United States, 63110
Novartis Investigative Site
St. Louis, Missouri, United States, 63141
United States, Montana
Novartis Investigative Site
Billings, Montana, United States, 59101
Novartis Investigative Site
Bozeman, Montana, United States, 59715
Novartis Investigative Site
Butte, Montana, United States, 59701
Novartis Investigative Site
Great Falls, Montana, United States, 59405
Novartis Investigative Site
Havre, Montana, United States, 59501
Novartis Investigative Site
Helena, Montana, United States, 59601
Novartis Investigative Site
Kalispell, Montana, United States, 59901
Novartis Investigative Site
Missoula, Montana, United States, 59801
Novartis Investigative Site
Missoula, Montana, United States, 59802
Novartis Investigative Site
Missoula, Montana, United States, 59804
United States, Nebraska
Novartis Investigative Site
Grand Island, Nebraska, United States, 68803
Novartis Investigative Site
Lincoln, Nebraska, United States, 68510
Novartis Investigative Site
Omaha, Nebraska, United States, 68106
Novartis Investigative Site
Omaha, Nebraska, United States, 68114
Novartis Investigative Site
Omaha, Nebraska, United States, 68122
Novartis Investigative Site
Omaha, Nebraska, United States, 68124
Novartis Investigative Site
Omaha, Nebraska, United States, 68131
Novartis Investigative Site
Omaha, Nebraska, United States, 68198
United States, Nevada
Novartis Investigative Site
Las Vegas, Nevada, United States, 89169
United States, New Hampshire
Novartis Investigative Site
Concord, New Hampshire, United States, 03301
Novartis Investigative Site
Exeter, New Hampshire, United States, 03833
Novartis Investigative Site
Hooksett, New Hampshire, United States, 03106
Novartis Investigative Site
Keene, New Hampshire, United States, 03431
Novartis Investigative Site
Laconia, New Hampshire, United States, 03246
Novartis Investigative Site
Lebanon, New Hampshire, United States, 03756
Novartis Investigative Site
Manchester, New Hampshire, United States, 03104
Novartis Investigative Site
Portsmouth, New Hampshire, United States, 03802
United States, New Jersey
Novartis Investigative Site
Hackensack, New Jersey, United States, 07601
Novartis Investigative Site
Hamilton, New Jersey, United States, 08690
Novartis Investigative Site
Livingston, New Jersey, United States, 07039
Novartis Investigative Site
Marlton, New Jersey, United States, 08053
Novartis Investigative Site
Morristown, New Jersey, United States, 07962
Novartis Investigative Site
Mount Holly, New Jersey, United States, 08060
Novartis Investigative Site
Neptune, New Jersey, United States, 7754
Novartis Investigative Site
New Brunswick, New Jersey, United States, 08901
Novartis Investigative Site
Pomona, New Jersey, United States, 08240
Novartis Investigative Site
Princeton, New Jersey, United States, 24740
Novartis Investigative Site
Ridgewood, New Jersey, United States, 07450
Novartis Investigative Site
Somerville, New Jersey, United States, 08876
Novartis Investigative Site
Sparta, New Jersey, United States, 07871
Novartis Investigative Site
Summit, New Jersey, United States, 07902
Novartis Investigative Site
Vineland, New Jersey, United States, 08360
Novartis Investigative Site
Voorhees, New Jersey, United States, 08043
United States, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico, United States, 87106
Novartis Investigative Site
Albuquerque, New Mexico, United States, 87110
Novartis Investigative Site
Las Cruces, New Mexico, United States, 88011
United States, New York
Novartis Investigative Site
Bronx, New York, United States, 10461
Novartis Investigative Site
Bronx, New York, United States, 10466
Novartis Investigative Site
Bronx, New York, United States, 10467-2490
Novartis Investigative Site
Buffalo, New York, United States, 14263
Novartis Investigative Site
Clifton Springs, New York, United States, 14432
Novartis Investigative Site
Cooperstown, New York, United States, 13326
Novartis Investigative Site
East Syracuse, New York, United States, 13057
Novartis Investigative Site
Elmhurst, New York, United States, 11373
Novartis Investigative Site
Jamaica, New York, United States, 11432
Novartis Investigative Site
Lake Success, New York, United States, 11042
Novartis Investigative Site
Manhasset, New York, United States, 11030
Novartis Investigative Site
Mineola, New York, United States, 11501
Novartis Investigative Site
New Hyde Park, New York, United States, 11042
Novartis Investigative Site
New York, New York, United States, 10011
Novartis Investigative Site
New York, New York, United States, 10016
Novartis Investigative Site
New York, New York, United States, 10029
Novartis Investigative Site
New York, New York, United States, 10032
Novartis Investigative Site
Rochester, New York, United States, 14620
Novartis Investigative Site
Rochester, New York, United States, 14623
Novartis Investigative Site
Rochester, New York, United States, 14642
Novartis Investigative Site
Stony Brook, New York, United States, 11794
Novartis Investigative Site
Syracuse, New York, United States, 13210
Novartis Investigative Site
Utica, New York, United States, 13502
United States, North Carolina
Novartis Investigative Site
Chapel Hill, North Carolina, United States, 27599
Novartis Investigative Site
Fayetteville, North Carolina, United States, 28304
Novartis Investigative Site
Gastonia, North Carolina, United States, 28053
Novartis Investigative Site
Goldsboro, North Carolina, United States, 27534
Novartis Investigative Site
Hendersonville, North Carolina, United States, 28791
Novartis Investigative Site
Kinston, North Carolina, United States, 28501
Novartis Investigative Site
Raleigh, North Carolina, United States, 27607
Novartis Investigative Site
Rutherfordton, North Carolina, United States, 28139
Novartis Investigative Site
Statesville, North Carolina, United States, 28677
Novartis Investigative Site
Washington, North Carolina, United States, 27889
Novartis Investigative Site
Winston-Salem, North Carolina, United States, 27157
United States, North Dakota
Novartis Investigative Site
Bismarck, North Dakota, United States, 58501
Novartis Investigative Site
Fargo, North Dakota, United States, 58122
Novartis Investigative Site
Grand Forks, North Dakota, United States, 58201
Novartis Investigative Site
Minot, North Dakota, United States, 58701
United States, Ohio
Novartis Investigative Site
Beachwood, Ohio, United States, 44122
Novartis Investigative Site
Bellefontaine, Ohio, United States, 43311
Novartis Investigative Site
Bowling Green, Ohio, United States, 43402
Novartis Investigative Site
Canton, Ohio, United States, 44708
Novartis Investigative Site
Canton, Ohio, United States, 44710
Novartis Investigative Site
Chillicothe, Ohio, United States, 54601
Novartis Investigative Site
Cincinnati, Ohio, United States, 45242
Novartis Investigative Site
Cincinnati, Ohio, United States, 45267
Novartis Investigative Site
Cleveland, Ohio, United States, 44111
Novartis Investigative Site
Cleveland, Ohio, United States, 44195
Novartis Investigative Site
Clyde, Ohio, United States, 43410
Novartis Investigative Site
Columbia, Ohio, United States, 43215
Novartis Investigative Site
Columbus, Ohio, United States, 43210
Novartis Investigative Site
Columbus, Ohio, United States, 43214
Novartis Investigative Site
Columbus, Ohio, United States, 43215
Novartis Investigative Site
Columbus, Ohio, United States, 43222
Novartis Investigative Site
Columbus, Ohio, United States, 43228
Novartis Investigative Site
Dayton, Ohio, United States, 45405
Novartis Investigative Site
Dayton, Ohio, United States, 45406
Novartis Investigative Site
Dayton, Ohio, United States, 45409
Novartis Investigative Site
Dayton, Ohio, United States, 45415
Novartis Investigative Site
Dayton, Ohio, United States, 45429
Novartis Investigative Site
Deleware, Ohio, United States, 43015
Novartis Investigative Site
Elyria, Ohio, United States, 44035
Novartis Investigative Site
Findlay, Ohio, United States, 45840
Novartis Investigative Site
Franklin, Ohio, United States, 45005-1066
Novartis Investigative Site
Greenville, Ohio, United States, 45331
Novartis Investigative Site
Independence, Ohio, United States, 44131
Novartis Investigative Site
Kettering, Ohio, United States, 45429
Novartis Investigative Site
Lambertville, Ohio, United States, 48144
Novartis Investigative Site
Lima, Ohio, United States, 45804
Novartis Investigative Site
Marietta, Ohio, United States, 45750
Novartis Investigative Site
Maumee, Ohio, United States, 43537
Novartis Investigative Site
Maumee, Ohio, United States, 43623
Novartis Investigative Site
Mayfield Heights, Ohio, United States, 44124
Novartis Investigative Site
Newark, Ohio, United States, 43055
Novartis Investigative Site
Oregon, Ohio, United States, 43616
Novartis Investigative Site
Sandusky, Ohio, United States, 44870
Novartis Investigative Site
Springfield, Ohio, United States, 45504
Novartis Investigative Site
Springfield, Ohio, United States, 45505
Novartis Investigative Site
Sylvania, Ohio, United States, 43560
Novartis Investigative Site
Tiffin, Ohio, United States, 44883
Novartis Investigative Site
Toledo, Ohio, United States, 43606
Novartis Investigative Site
Toledo, Ohio, United States, 43608
Novartis Investigative Site
Toledo, Ohio, United States, 43614
Novartis Investigative Site
Toledo, Ohio, United States, 43617
Novartis Investigative Site
Toledo, Ohio, United States, 43623
Novartis Investigative Site
Troy, Ohio, United States, 45373
Novartis Investigative Site
Wauseon, Ohio, United States, 43567
Novartis Investigative Site
Westerville, Ohio, United States, 43081
Novartis Investigative Site
Wilmington, Ohio, United States, 45177
Novartis Investigative Site
Wooster, Ohio, United States, 44691
Novartis Investigative Site
Wpafb, Ohio, United States, 45433
Novartis Investigative Site
Xenia, Ohio, United States, 45385
Novartis Investigative Site
Zanesville, Ohio, United States, 43701
United States, Oklahoma
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73104
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73112
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73120
Novartis Investigative Site
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Novartis Investigative Site
Coos Bay, Oregon, United States, 97420
Novartis Investigative Site
Eugene, Oregon, United States, 97401
Novartis Investigative Site
Glesham, Oregon, United States, 97030
Novartis Investigative Site
Hillsboro, Oregon, United States, 97123
Novartis Investigative Site
Klamath Falls, Oregon, United States, 97601
Novartis Investigative Site
Milwaukie, Oregon, United States, 97222
Novartis Investigative Site
Portland, Oregon, United States, 97210
Novartis Investigative Site
Portland, Oregon, United States, 97213
Novartis Investigative Site
Portland, Oregon, United States, 97216
Novartis Investigative Site
Portland, Oregon, United States, 97225
Novartis Investigative Site
Portland, Oregon, United States, 97227
Novartis Investigative Site
Portland, Oregon, United States, 97239
Novartis Investigative Site
Tualatin, Oregon, United States, 97062
United States, Pennsylvania
Novartis Investigative Site
Abington, Pennsylvania, United States, 19001-3788
Novartis Investigative Site
Bethlehem, Pennsylvania, United States, 18015
Novartis Investigative Site
Bryn Mawr, Pennsylvania, United States, 19010
Novartis Investigative Site
Butler, Pennsylvania, United States, 16001
Novartis Investigative Site
Danville, Pennsylvania, United States, 17822-2001
Novartis Investigative Site
Ephrata, Pennsylvania, United States, 17522
Novartis Investigative Site
Hazelton, Pennsylvania, United States, 18201
Novartis Investigative Site
Hershey, Pennsylvania, United States, 17033
Novartis Investigative Site
Kingston, Pennsylvania, United States, 18704
Novartis Investigative Site
Lancaster, Pennsylvania, United States, 17604
Novartis Investigative Site
Langhorne, Pennsylvania, United States, 19047
Novartis Investigative Site
Lewistown, Pennsylvania, United States, 17044
Novartis Investigative Site
Media, Pennsylvania, United States, 19063
Novartis Investigative Site
Nashville, Pennsylvania, United States, 37204
Novartis Investigative Site
Paoli, Pennsylvania, United States, 19301
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19107-2568
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19107
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19111
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19114
Novartis Investigative Site
Phoenixville, Pennsylvania, United States, 19460
Novartis Investigative Site
Pottstown, Pennsylvania, United States, 19464
Novartis Investigative Site
Sayre, Pennsylvania, United States, 18840
Novartis Investigative Site
Scranton, Pennsylvania, United States, 18508
Novartis Investigative Site
Sellersville, Pennsylvania, United States, 18960
Novartis Investigative Site
State College, Pennsylvania, United States, 16801
Novartis Investigative Site
State College, Pennsylvania, United States, 16803
Novartis Investigative Site
West Reading, Pennsylvania, United States, 19612
Novartis Investigative Site
Wilkes-Barre, Pennsylvania, United States, 18711
Novartis Investigative Site
Wilkes-Barre, Pennsylvania, United States, 18765
Novartis Investigative Site
Wynnewood, Pennsylvania, United States, 19096
United States, Rhode Island
Novartis Investigative Site
Providence, Rhode Island, United States, 02903
Novartis Investigative Site
Providence, Rhode Island, United States, 02905
Novartis Investigative Site
Providence, Rhode Island, United States, 02906
Novartis Investigative Site
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Novartis Investigative Site
Anderson, South Carolina, United States, 29621
Novartis Investigative Site
Charleston, South Carolina, United States, 29425
Novartis Investigative Site
Columbia, South Carolina, United States, 29210
Novartis Investigative Site
Greenville, South Carolina, United States, 29605
Novartis Investigative Site
Mt. Pleasant, South Carolina, United States, 29464
Novartis Investigative Site
Spartanburg, South Carolina, United States, 29303
United States, South Dakota
Novartis Investigative Site
Aberdeen, South Dakota, United States, 57401
Novartis Investigative Site
Rapid City, South Dakota, United States, 57701
Novartis Investigative Site
Sioux Falls, South Dakota, United States, 57104
Novartis Investigative Site
Sioux Falls, South Dakota, United States, 57105
Novartis Investigative Site
Sioux Falls, South Dakota, United States, 57117-5134
United States, Tennessee
Novartis Investigative Site
Chattanooga, Tennessee, United States, 37403
Novartis Investigative Site
Chattanooga, Tennessee, United States, 37404
Novartis Investigative Site
Franklin, Tennessee, United States, 37067
Novartis Investigative Site
Jackson, Tennessee, United States, 38301
Novartis Investigative Site
Knoxville, Tennessee, United States, 37909
Novartis Investigative Site
Knoxville, Tennessee, United States, 37916
Novartis Investigative Site
Knoxville, Tennessee, United States, 37920
Novartis Investigative Site
Memphis, Tennessee, United States, 38120
Novartis Investigative Site
Nashville, Tennessee, United States, 37203
Novartis Investigative Site
Nashville, Tennessee, United States, 37208
Novartis Investigative Site
Nashville, Tennessee, United States, 37232
United States, Texas
Novartis Investigative Site
Abilene, Texas, United States, 79606-5208
Novartis Investigative Site
Amarillo, Texas, United States, 79106
Novartis Investigative Site
Austin, Texas, United States, 78705
Novartis Investigative Site
Austin, Texas, United States, 78731
Novartis Investigative Site
Austin, Texas, United States, 78745
Novartis Investigative Site
Austin, Texas, United States, 78758
Novartis Investigative Site
Beaumont, Texas, United States, 77702-1449
Novartis Investigative Site
Bedford, Texas, United States, 76022
Novartis Investigative Site
Cedar Park, Texas, United States, 78613
Novartis Investigative Site
Dallas, Texas, United States, 75230
Novartis Investigative Site
Dallas, Texas, United States, 75237
Novartis Investigative Site
Fort Sam Houston, Texas, United States, 78234
Novartis Investigative Site
Fort Worth, Texas, United States, 76104
Novartis Investigative Site
Houston, Texas, United States, 77030
Novartis Investigative Site
Lackland Air Force Base, Texas, United States, 78236
Novartis Investigative Site
Longview, Texas, United States, 75601
Novartis Investigative Site
McAllen, Texas, United States, 78503-1298
Novartis Investigative Site
Mesquite, Texas, United States, 75150
Novartis Investigative Site
Midland, Texas, United States, 79701
Novartis Investigative Site
Paris, Texas, United States, 75460
Novartis Investigative Site
Round Rock, Texas, United States, 78655
Novartis Investigative Site
Round Rock, Texas, United States, 78681
Novartis Investigative Site
San Antonio, Texas, United States, 78209
Novartis Investigative Site
San Antonio, Texas, United States, 78229
Novartis Investigative Site
San Marcos, Texas, United States, 78666
Novartis Investigative Site
Sherman, Texas, United States, 75090
Novartis Investigative Site
Sugar Land, Texas, United States, 77479
Novartis Investigative Site
Tyler, Texas, United States, 75702
Novartis Investigative Site
Waco, Texas, United States, 76712
Novartis Investigative Site
Wichita Falls, Texas, United States, 76310
United States, Utah
Novartis Investigative Site
Salt Lake City, Utah, United States, 84112
United States, Vermont
Novartis Investigative Site
Berlin, Vermont, United States, 05602
Novartis Investigative Site
Burlington, Vermont, United States, 05401
Novartis Investigative Site
Saint Johnsbury, Vermont, United States, 05819
United States, Virginia
Novartis Investigative Site
Charlottesville, Virginia, United States, 22902
Novartis Investigative Site
Danville, Virginia, United States, 24541
Novartis Investigative Site
Fredricksburg, Virginia, United States, 22401
Novartis Investigative Site
Hampton, Virginia, United States, 23666
Novartis Investigative Site
Norfolk, Virginia, United States, 23502
Novartis Investigative Site
Richmond, Virginia, United States, 23230
Novartis Investigative Site
Roanoke, Virginia, United States, 24014
United States, Washington
Novartis Investigative Site
Auburn, Washington, United States, 98002
Novartis Investigative Site
Bellingham, Washington, United States, 98225
Novartis Investigative Site
Bremerton, Washington, United States, 98310
Novartis Investigative Site
Burien, Washington, United States, 98166
Novartis Investigative Site
Centralia, Washington, United States, 98531
Novartis Investigative Site
Federal way, Washington, United States, 98003
Novartis Investigative Site
Kennewick, Washington, United States, 99336
Novartis Investigative Site
Kirkland, Washington, United States
Novartis Investigative Site
Mount Vernon, Washington, United States, 98273
Novartis Investigative Site
Olympia, Washington, United States, 98506
Novartis Investigative Site
Port Angeles, Washington, United States, 98362
Novartis Investigative Site
Poulsbo, Washington, United States, 98370
Novartis Investigative Site
Puyallup, Washington, United States, 98372
Novartis Investigative Site
Renton, Washington, United States, 98055
Novartis Investigative Site
Seattle, Washington, United States, 98104
Novartis Investigative Site
Seattle, Washington, United States, 98112
Novartis Investigative Site
Seattle, Washington, United States, 98122-4299
Novartis Investigative Site
Seattle, Washington, United States, 98122
Novartis Investigative Site
Seattle, Washington, United States, 98133
Novartis Investigative Site
Seattle, Washington, United States, 98195-6098
Novartis Investigative Site
Spokane, Washington, United States, 99202
Novartis Investigative Site
Spokane, Washington, United States, 99218
Novartis Investigative Site
Tacoma, Washington, United States, 98405
Novartis Investigative Site
Tacoma, Washington, United States, 98415
Novartis Investigative Site
Tacoma, Washington, United States, 98499
Novartis Investigative Site
Vancouver, Washington, United States, 98668
Novartis Investigative Site
Vancouver, Washington, United States, 98686
Novartis Investigative Site
Wenatchee, Washington, United States, 98801
United States, West Virginia
Novartis Investigative Site
Charleston, West Virginia, United States, 25304
Novartis Investigative Site
Huntington, West Virginia, United States, 25701
Novartis Investigative Site
Wheeling, West Virginia, United States, 26003
United States, Wisconsin
Novartis Investigative Site
Appleton, Wisconsin, United States, 54915
Novartis Investigative Site
Chippewa Falls, Wisconsin, United States, 54729
Novartis Investigative Site
Eau Claire, Wisconsin, United States, 54701
Novartis Investigative Site
Eau Claire, Wisconsin, United States, 54702
Novartis Investigative Site
Green Bay, Wisconsin, United States, 54301
Novartis Investigative Site
Green Bay, Wisconsin, United States, 54303
Novartis Investigative Site
La Crosse, Wisconsin, United States, 54601
Novartis Investigative Site
Madison, Wisconsin, United States, 53717
Novartis Investigative Site
Manitowoc, Wisconsin, United States, 54221
Novartis Investigative Site
Marinette, Wisconsin, United States, 54143
Novartis Investigative Site
Marshfield, Wisconsin, United States, 54449
Novartis Investigative Site
Milwaukee, Wisconsin, United States, 53233
Novartis Investigative Site
Minocqua, Wisconsin, United States, 54548
Novartis Investigative Site
Oconto Falls, Wisconsin, United States, 54154
Novartis Investigative Site
Oshkosh, Wisconsin, United States, 54904
Novartis Investigative Site
Rhinelander, Wisconsin, United States, 54501
Novartis Investigative Site
Rice Lake, Wisconsin, United States, 54868
Novartis Investigative Site
Stevens Point, Wisconsin, United States, 54481
Novartis Investigative Site
Sturgeon Bay, Wisconsin, United States, 54235
Novartis Investigative Site
Weston, Wisconsin, United States, 54476
Novartis Investigative Site
Wisconsin Rapids, Wisconsin, United States, 54494
United States, Wyoming
Novartis Investigative Site
Casper, Wyoming, United States, 82609
Novartis Investigative Site
Sheridan, Wyoming, United States, 82801
Argentina
Novartis Investigative Site
Berazategui, Buenos Aires, Argentina, B1880BBF
Novartis Investigative Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1185AAT
Novartis Investigative Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1125ABD
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000KZE
Novartis Investigative Site
Ciudad Autónoma de Buenos Aires, Argentina, C1417DTN
Novartis Investigative Site
Mendoza, Argentina, M5500AYB
Novartis Investigative Site
Quilmes, Argentina, 1878
Novartis Investigative Site
Santa Fe, Argentina, 3000
Novartis Investigative Site
Tucuman, Argentina, 4000
Australia, New South Wales
Novartis Investigative Site
Camperdown, New South Wales, Australia, 2050
Novartis Investigative Site
Coffs Harbour, New South Wales, Australia, 2450
Novartis Investigative Site
Concord, New South Wales, Australia, 2139
Novartis Investigative Site
Kingswood, New South Wales, Australia, 2747
Novartis Investigative Site
Liverpool, New South Wales, Australia, 2170
Novartis Investigative Site
North Sydney, New South Wales, Australia, 2060
Novartis Investigative Site
Port Macquarie, New South Wales, Australia, 2444
Novartis Investigative Site
Randwick, New South Wales, Australia, 2031
Novartis Investigative Site
Taree, New South Wales, Australia, 2430
Novartis Investigative Site
Tweed Heads, New South Wales, Australia, 2485
Novartis Investigative Site
Wagga Wagga, New South Wales, Australia, 2650
Novartis Investigative Site
Waratah, New South Wales, Australia, 2298
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Novartis Investigative Site
Nambour, Queensland, Australia, 4560
Novartis Investigative Site
South Brisbane, Queensland, Australia, 4101
Novartis Investigative Site
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
Novartis Investigative Site
Adelaide, South Australia, Australia, 5000
Novartis Investigative Site
Bedford Park, South Australia, Australia, 5042
Novartis Investigative Site
Woodville, South Australia, Australia, 5011
Australia, Tasmania
Novartis Investigative Site
Hobart, Tasmania, Australia, 7000
Australia, Victoria
Novartis Investigative Site
Box Hill, Victoria, Australia, 3128
Novartis Investigative Site
East Bentleigh, Victoria, Australia, 3165
Novartis Investigative Site
East Melbourne, Victoria, Australia, 3002
Novartis Investigative Site
Fitzroy, Victoria, Australia, 3065
Novartis Investigative Site
Footscray, Victoria, Australia, 3011
Novartis Investigative Site
Frankston, Victoria, Australia, 3199
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Novartis Investigative Site
Melbourne, Victoria, Australia, 3002
Novartis Investigative Site
Parkville, Victoria, Australia, 3050
Novartis Investigative Site
Ringwood East, Victoria, Australia, 3135
Novartis Investigative Site
Wendouree, Victoria, Australia, 3355
Australia, Western Australia
Novartis Investigative Site
Bunbury, Western Australia, Australia, 6230
Novartis Investigative Site
Nedlands, Western Australia, Australia, 6009
Novartis Investigative Site
Subiaco, Western Australia, Australia, 6008
Australia
Novartis Investigative Site
Campbelltown, Australia, 2560
Novartis Investigative Site
Lismore, Australia, 2480
Novartis Investigative Site
Murdoch, Australia, 6150
Austria
Novartis Investigative Site
Guessing, Austria, 7540
Novartis Investigative Site
Linz, Austria, A-4020
Novartis Investigative Site
Rankweil, Austria, A-6830
Novartis Investigative Site
Salzburg, Austria, A-5020
Novartis Investigative Site
Steyr, Austria, 4400
Novartis Investigative Site
Vienna, Austria, 1140
Novartis Investigative Site
Villach, Austria, 9500
Novartis Investigative Site
Wien, Austria, A-1090
Belgium
Novartis Investigative Site
Aalst, Belgium, 9300
Novartis Investigative Site
Antwerpen, Belgium, 2020
Novartis Investigative Site
Bonheiden, Belgium, 2820
Novartis Investigative Site
Brasschaat, Belgium, 2930
Novartis Investigative Site
Brugge, Belgium, 8000
Novartis Investigative Site
Brussels, Belgium, 1000
Novartis Investigative Site
Brussels, Belgium, 1070
Novartis Investigative Site
Brussel, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1020
Novartis Investigative Site
Bruxelles, Belgium, 1050
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Charleroi, Belgium, 6000
Novartis Investigative Site
Edegem, Belgium, 2650
Novartis Investigative Site
Genk, Belgium, 3600
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Haine Saint Paul, Belgium, 7100
Novartis Investigative Site
Hasselt, Belgium, 3500
Novartis Investigative Site
Huy, Belgium, 4500
Novartis Investigative Site
Kortrijk, Belgium, 8500
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Liège, Belgium, 4000
Novartis Investigative Site
Mons, Belgium, 7000
Novartis Investigative Site
Namur, Belgium, 5000
Novartis Investigative Site
Roeselare, Belgium, 8800
Novartis Investigative Site
Sint-Niklaas, Belgium, 9100
Novartis Investigative Site
Tournai, Belgium, 7500
Novartis Investigative Site
Turnhout, Belgium, 2300
Novartis Investigative Site
Verviers, Belgium, 4800
Novartis Investigative Site
Wilrijk, Belgium, 2610
Novartis Investigative Site
Yvoir, Belgium, 5530
Brazil
Novartis Investigative Site
Salvador, Bahía, Brazil, 40.050-410
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil, 30150-270
Novartis Investigative Site
Porte Alegre, Rio Grande Do Sul, Brazil, 90430-001
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-003
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90050-170
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90430-090
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90560-030
Novartis Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610000
Novartis Investigative Site
Jaú, São Paulo, Brazil, 17210-120
Novartis Investigative Site
Santo André, São Paulo, Brazil, 09060-650
Novartis Investigative Site
Rio de Janeiro, Brazil, 20560-120
Bulgaria
Novartis Investigative Site
Shumen, Bulgaria, 9700
Novartis Investigative Site
Sofia, Bulgaria, 1527
Novartis Investigative Site
Sofia, Bulgaria, 1756
Novartis Investigative Site
Varna, Bulgaria, 9010
Canada, British Columbia
Novartis Investigative Site
Kelowna, British Columbia, Canada, V1Y 5L3
Novartis Investigative Site
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, New Brunswick
Novartis Investigative Site
Moncton, New Brunswick, Canada, E1C 8X3
Novartis Investigative Site
Saint John, New Brunswick, Canada, E2L 4L2
Canada, Ontario
Novartis Investigative Site
Barrie, Ontario, Canada, L4M 6M2
Novartis Investigative Site
London, Ontario, Canada, N6A 4L6
Novartis Investigative Site
Sault Ste. Marie, Ontario, Canada, P6A 2C4
Novartis Investigative Site
St Catharines, Ontario, Canada, L2R 7C6
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Prince Edward Island
Novartis Investigative Site
Charlottetown, Prince Edward Island, Canada, C1A 8T5
Canada, Quebec
Novartis Investigative Site
Sherbrooke, Quebec, Canada, J1H 5N4
Canada, Saskatchewan
Novartis Investigative Site
Regina, Saskatchewan, Canada, S4T 7T1
Chile
Novartis Investigative Site
Temuco, Región De La Araucania, Chile, 481-0469
Novartis Investigative Site
Valdivia, Región De Los Lagos, Chile, 5090145
Novartis Investigative Site
Santiago, Región Metro De Santiago, Chile, 7500921
Novartis Investigative Site
Santiago, Región Metro De Santiago, Chile, 7650635
Novartis Investigative Site
Santiago, Región Metro De Santiago, Chile, 8360160
Novartis Investigative Site
Santiago, Región Metro De Santiago, Chile, 8380455
Novartis Investigative Site
Valparaiso, Valparaíso, Chile, 2341131
Novartis Investigative Site
Viña del Mar, Valparaíso, Chile, 254-0364
Novartis Investigative Site
Arica, Chile, 1000871
China, Guangdong
Novartis Investigative Site
Guangzhou, Guangdong, China, 510060
China
Novartis Investigative Site
Beijing, China, 100021
Novartis Investigative Site
Beijing, China, 100071
Novartis Investigative Site
Shanghai, China, 200032
Novartis Investigative Site
Tianjin, China, 300060
Croatia
Novartis Investigative Site
Varaždin, Croatia
Novartis Investigative Site
Zagreb, Croatia, 10 000
Novartis Investigative Site
Zagreb, Croatia, 10000
Czech Republic
Novartis Investigative Site
Brno, Czech Republic, 625 00
Novartis Investigative Site
Brno, Czech Republic, 656 53
Novartis Investigative Site
Brno, Czech Republic, 656 91
Novartis Investigative Site
Ceske Budejovice, Czech Republic, 370 87
Novartis Investigative Site
Chomutov, Czech Republic, 43012
Novartis Investigative Site
Jihlava, Czech Republic, 586 01
Novartis Investigative Site
Novy Jicin, Czech Republic, 741 01
Novartis Investigative Site
Olomouc, Czech Republic, 775 20
Novartis Investigative Site
Pardubice, Czech Republic, 532 03
Novartis Investigative Site
Praha 10, Czech Republic, 100 34
Novartis Investigative Site
Praha 2, Czech Republic, 12808
Novartis Investigative Site
Praha 4, Czech Republic, 140 59
Novartis Investigative Site
Praha 5, Czech Republic, 150 08
Novartis Investigative Site
Praha 8, Czech Republic, 180 00
Novartis Investigative Site
Usti nad Labem, Czech Republic, 40113
Denmark
Novartis Investigative Site
Aalborg, Denmark, 9100
Novartis Investigative Site
Esbjerg, Denmark, 6700
Novartis Investigative Site
Herlev, Denmark, DK-2730
Novartis Investigative Site
Hillerød, Denmark, 3400
Novartis Investigative Site
Koebenhavn Oe, Denmark, 2100
Novartis Investigative Site
Naestved, Denmark, 4700
Novartis Investigative Site
Odense, Denmark, 5000
Novartis Investigative Site
Roskilde, Denmark, 4000
Novartis Investigative Site
Vejle, Denmark, 7100
Novartis Investigative Site
Viborg, Denmark, 8800
Novartis Investigative Site
Århus C, Denmark, 8000
Estonia
Novartis Investigative Site
Tallinn, Estonia, 13419
Novartis Investigative Site
Tartu, Estonia, 51014
France
Novartis Investigative Site
Angers Cedex 01, France, 49033
Novartis Investigative Site
Annecy, France, 74000
Novartis Investigative Site
Avignon, France, 84000
Novartis Investigative Site
Bayonne, France, 64100
Novartis Investigative Site
Bethune, France, 62400
Novartis Investigative Site
Bordeaux, France, 33000
Novartis Investigative Site
Brive La Gaillarde, France, 19100
Novartis Investigative Site
Bron, France, 69677
Novartis Investigative Site
Caen Cedex 05, France, 14076
Novartis Investigative Site
Caen, France, 14000
Novartis Investigative Site
Clermont Ferrand, France, 63000
Novartis Investigative Site
Coudekerque Branche, France, 59210
Novartis Investigative Site
Dijon Cedex, France, 21079
Novartis Investigative Site
Dijon, France, 21000
Novartis Investigative Site
Draguignan, France, 83007
Novartis Investigative Site
Grenoble Cedex 9, France, 38043
Novartis Investigative Site
Grenoble Cedex, France, 38028
Novartis Investigative Site
Hyeres, France, 83400
Novartis Investigative Site
La Seyne Sur Mer, France, 83500
Novartis Investigative Site
Le Chesnay, France, 78157
Novartis Investigative Site
Le Havre, France, 76600
Novartis Investigative Site
Le Mans, France, 72000
Novartis Investigative Site
Lille, France, 59000
Novartis Investigative Site
Lyon, France, 69008
Novartis Investigative Site
Lyon, France, 69009
Novartis Investigative Site
Lyon, France, 69373
Novartis Investigative Site
Marseille Cedex 09, France, 13273
Novartis Investigative Site
Marseille cedex 5, France, 13385
Novartis Investigative Site
Marseille, France, 13285
Novartis Investigative Site
Metz cedex 01, France, 57045
Novartis Investigative Site
Mont de Marsan, France, 40024
Novartis Investigative Site
Montauban, France, 82000
Novartis Investigative Site
Montbeliard, France, 25200
Novartis Investigative Site
Mulhouse, France, 68070
Novartis Investigative Site
Nancy, France, 54100
Novartis Investigative Site
Nice Cedex 2, France, 06189
Novartis Investigative Site
Nimes, France, 30907
Novartis Investigative Site
Paris Cedex 10, France, 75475
Novartis Investigative Site
Paris Cedex 5, France, 75248
Novartis Investigative Site
Paris, France, 75014
Novartis Investigative Site
Perigueux, France, 24004
Novartis Investigative Site
Perpignan, France, 66000
Novartis Investigative Site
Reims, France, 51100
Novartis Investigative Site
Rouen cedex 1, France, 76038
Novartis Investigative Site
Rouen, France, 76000
Novartis Investigative Site
Saint Brieuc, France, 22015 cedex
Novartis Investigative Site
Saint Grégoire, France, 35760
Novartis Investigative Site
Saint Jean, France, 31240
Novartis Investigative Site
Saint-Cloud, France, 92210
Novartis Investigative Site
Saint-Herblain, France, 44805
Novartis Investigative Site
Saint-Martin Boulogne, France, 62280
Novartis Investigative Site
Saint-Priest en Jarez Cedex, France, 42271
Novartis Investigative Site
Strasbourg, France, 67000
Novartis Investigative Site
Strasbourg, France, 67085
Novartis Investigative Site
Toulouse, France, 31077
Novartis Investigative Site
Toulouse, France, 31300
Novartis Investigative Site
Tours, France, 37044
Novartis Investigative Site
Valenciennes, France, 59300
Novartis Investigative Site
Vandoeuvre-Les-Nancy, France, 54511
Novartis Investigative Site
Villejuif Cedex, France, 94805
Germany
Novartis Investigative Site
Aalen, Baden-Wuerttemberg, Germany, 73430
Novartis Investigative Site
Baden-Baden, Baden-Wuerttemberg, Germany, 76532
Novartis Investigative Site
Boeblingen, Baden-Wuerttemberg, Germany, 71032
Novartis Investigative Site
Emmendingen, Baden-Wuerttemberg, Germany, 79312
Novartis Investigative Site
Esslingen, Baden-Wuerttemberg, Germany, 73730
Novartis Investigative Site
Freiburg, Baden-Wuerttemberg, Germany, 79106
Novartis Investigative Site
Goeppingen, Baden-Wuerttemberg, Germany, 73035
Novartis Investigative Site
Heidelberg, Baden-Wuerttemberg, Germany, 69115
Novartis Investigative Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
Novartis Investigative Site
Karlsruhe, Baden-Wuerttemberg, Germany, 76133
Novartis Investigative Site
Karlsruhe, Baden-Wuerttemberg, Germany, 76135
Novartis Investigative Site
Karlsruhe, Baden-Wuerttemberg, Germany, 76199
Novartis Investigative Site
Konstanz, Baden-Wuerttemberg, Germany, 78464
Novartis Investigative Site
Loerrach, Baden-Wuerttemberg, Germany, 79539
Novartis Investigative Site
Ludwigsburg, Baden-Wuerttemberg, Germany, 71640
Novartis Investigative Site
Mannheim, Baden-Wuerttemberg, Germany, 68165
Novartis Investigative Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
Novartis Investigative Site
Mutlangen, Baden-Wuerttemberg, Germany, 73557
Novartis Investigative Site
Ostfildern, Baden-Wuerttemberg, Germany, 73760
Novartis Investigative Site
Ravensburg, Baden-Wuerttemberg, Germany, 88212
Novartis Investigative Site
Reutlingen, Baden-Wuerttemberg, Germany, 72764
Novartis Investigative Site
Rheinfelden, Baden-Wuerttemberg, Germany, 79618
Novartis Investigative Site
Schwaebisch Hall, Baden-Wuerttemberg, Germany, 74523
Novartis Investigative Site
Schwetzingen, Baden-Wuerttemberg, Germany, 68723
Novartis Investigative Site
Sigmaringen, Baden-Wuerttemberg, Germany, 72488
Novartis Investigative Site
Stuttgart, Baden-Wuerttemberg, Germany, 70174
Novartis Investigative Site
Stuttgart, Baden-Wuerttemberg, Germany, 70376
Novartis Investigative Site
Tuebingen, Baden-Wuerttemberg, Germany, 72076
Novartis Investigative Site
Tuttlingen, Baden-Wuerttemberg, Germany, 78532
Novartis Investigative Site
Ulm, Baden-Wuerttemberg, Germany, 89075
Novartis Investigative Site
Villingen-Schwenningen, Baden-Wuerttemberg, Germany, 78050
Novartis Investigative Site
Ansbach, Bayern, Germany, 91522
Novartis Investigative Site
Aschaffenburg, Bayern, Germany, 63739
Novartis Investigative Site
Augsburg, Bayern, Germany, 86156
Novartis Investigative Site
Bad Reichenhall, Bayern, Germany, 83435
Novartis Investigative Site
Bayreuth, Bayern, Germany, 95445
Novartis Investigative Site
Coburg, Bayern, Germany, 96450
Novartis Investigative Site
Dachau, Bayern, Germany, 85221
Novartis Investigative Site
Deggendorf, Bayern, Germany, 94469
Novartis Investigative Site
Donauwoerth, Bayern, Germany, 86609
Novartis Investigative Site
Ebersberg, Bayern, Germany, 85560
Novartis Investigative Site
Eggenfelden, Bayern, Germany, 84307
Novartis Investigative Site
Erlangen, Bayern, Germany, 91054
Novartis Investigative Site
Forchheim, Bayern, Germany, 91301
Novartis Investigative Site
Freising, Bayern, Germany, 85354
Novartis Investigative Site
Fuerth, Bayern, Germany, 90766
Novartis Investigative Site
Garmisch-Partenkirchen, Bayern, Germany, 82467
Novartis Investigative Site
Kempten, Bayern, Germany, 87439
Novartis Investigative Site
Kronach, Bayern, Germany, 96317
Novartis Investigative Site
Landshut, Bayern, Germany, 84028
Novartis Investigative Site
Landshut, Bayern, Germany, 84034
Novartis Investigative Site
Marktredwitz, Bayern, Germany, 95615
Novartis Investigative Site
Memmingen, Bayern, Germany, 87700
Novartis Investigative Site
Muenchen, Bayern, Germany, 80331
Novartis Investigative Site
Muenchen, Bayern, Germany, 80335
Novartis Investigative Site
Muenchen, Bayern, Germany, 80337
Novartis Investigative Site
Muenchen, Bayern, Germany, 80637
Novartis Investigative Site
Muenchen, Bayern, Germany, 81675
Novartis Investigative Site
Muenchen, Bayern, Germany, 81925
Novartis Investigative Site
Muhr, Bayern, Germany, 91735
Novartis Investigative Site
München, Bayern, Germany, 80638
Novartis Investigative Site
Nuernberg, Bayern, Germany, 90449
Novartis Investigative Site
Nuernberg, Bayern, Germany, 90491
Novartis Investigative Site
Regensburg, Bayern, Germany, 93053
Novartis Investigative Site
Rosenheim, Bayern, Germany, 83022
Novartis Investigative Site
Roth, Bayern, Germany, 91154
Novartis Investigative Site
Schwandorf, Bayern, Germany, 92421
Novartis Investigative Site
Traunstein, Bayern, Germany, 83278
Novartis Investigative Site
Waldmuenchen, Bayern, Germany, 93449
Novartis Investigative Site
Weiden, Bayern, Germany, 92637
Novartis Investigative Site
Fuerstenwalde, Brandenburg, Germany, 15517
Novartis Investigative Site
Koenigs Wusterhausen, Brandenburg, Germany, 15711
Novartis Investigative Site
Luckenwalde, Brandenburg, Germany, 14943
Novartis Investigative Site
Ludwigsfelde, Brandenburg, Germany, 14974
Novartis Investigative Site
Bremerhaven, Bremen, Germany, 27574
Novartis Investigative Site
Bad Soden, Hessen, Germany, 65812
Novartis Investigative Site
Frankfurt am Main, Hessen, Germany, 60590
Novartis Investigative Site
Frankfurt, Hessen, Germany, 60389
Novartis Investigative Site
Frankfurt, Hessen, Germany, 60596
Novartis Investigative Site
Frankfurt, Hessen, Germany, 65929
Novartis Investigative Site
Fulda, Hessen, Germany, 36043
Novartis Investigative Site
Hanau, Hessen, Germany, 63450
Novartis Investigative Site
Kassel, Hessen, Germany, 34117
Novartis Investigative Site
Kassel, Hessen, Germany, 34125
Novartis Investigative Site
Limburg, Hessen, Germany, 65549
Novartis Investigative Site
Marburg, Hessen, Germany, 35043
Novartis Investigative Site
Offenbach, Hessen, Germany, 63069
Novartis Investigative Site
Wiesbaden, Hessen, Germany, 65189
Novartis Investigative Site
Wiesbaden, Hessen, Germany, 65191
Novartis Investigative Site
Wiesbaden, Hessen, Germany, 65197
Novartis Investigative Site
Wiesbaden, Hessen, Germany, 65199
Novartis Investigative Site
Greifswald, Mecklenburg-Vorpommern, Germany, 17487
Novartis Investigative Site
Guestrow, Mecklenburg-Vorpommern, Germany, 18273
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, Germany, 18059
Novartis Investigative Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19055
Novartis Investigative Site
Stralsund, Mecklenburg-Vorpommern, Germany, 18435
Novartis Investigative Site
Aurich, Niedersachsen, Germany, 26603
Novartis Investigative Site
Braunschweig, Niedersachsen, Germany, 38100
Novartis Investigative Site
Celle, Niedersachsen, Germany, 29223
Novartis Investigative Site
Cuxhaven, Niedersachsen, Germany, 27474
Novartis Investigative Site
Georgsmarienhuette, Niedersachsen, Germany, 49124
Novartis Investigative Site
Goettingen, Niedersachsen, Germany, 37075
Novartis Investigative Site
Goslar, Niedersachsen, Germany, 38642
Novartis Investigative Site
Hameln, Niedersachsen, Germany, 31785
Novartis Investigative Site
Hannover, Niedersachsen, Germany, 30177
Novartis Investigative Site
Hannover, Niedersachsen, Germany, 30559
Novartis Investigative Site
Hannover, Niedersachsen, Germany, 30625
Novartis Investigative Site
Leer, Niedersachsen, Germany, 26789
Novartis Investigative Site
Oldenburg, Niedersachsen, Germany, 26121
Novartis Investigative Site
Oldenburg, Niedersachsen, Germany, 26133
Novartis Investigative Site
Osnabrueck, Niedersachsen, Germany, 49074
Novartis Investigative Site
Rotenburg (Wuemme), Niedersachsen, Germany, 27356
Novartis Investigative Site
Stade, Niedersachsen, Germany, 21680
Novartis Investigative Site
Stadthagen, Niedersachsen, Germany, 31655
Novartis Investigative Site
Vechta, Niedersachsen, Germany, 49377
Novartis Investigative Site
Westerstede, Niedersachsen, Germany, 26655
Novartis Investigative Site
Bergisch Gladbach, Nordrhein-Westfalen, Germany, 51465
Novartis Investigative Site
Bielefeld, Nordrhein-Westfalen, Germany, 33604
Novartis Investigative Site
Bochum, Nordrhein-Westfalen, Germany, 44787
Novartis Investigative Site
Bochum, Nordrhein-Westfalen, Germany, 44791
Novartis Investigative Site
Bonn, Nordrhein-Westfalen, Germany, 53113
Novartis Investigative Site
Bonn, Nordrhein-Westfalen, Germany, 53127
Novartis Investigative Site
Bonn, Nordrhein-Westfalen, Germany, 53129
Novartis Investigative Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40225
Novartis Investigative Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40325
Novartis Investigative Site
Duisburg, Nordrhein-Westfalen, Germany, 47166
Novartis Investigative Site
Eschweiler, Nordrhein-Westfalen, Germany, 52249
Novartis Investigative Site
Essen, Nordrhein-Westfalen, Germany, 45122
Novartis Investigative Site
Essen, Nordrhein-Westfalen, Germany, 45130
Novartis Investigative Site
Essen, Nordrhein-Westfalen, Germany, 45131
Novartis Investigative Site
Essen, Nordrhein-Westfalen, Germany, 45136
Novartis Investigative Site
Gummersbach, Nordrhein-Westfalen, Germany, 51643
Novartis Investigative Site
Hamm-Heessen, Nordrhein-Westfalen, Germany, 59073
Novartis Investigative Site
Herne, Nordrhein-Westfalen, Germany, 44623
Novartis Investigative Site
Koeln, Nordrhein-Westfalen, Germany, 50677
Novartis Investigative Site
Koeln, Nordrhein-Westfalen, Germany, 50935
Novartis Investigative Site
Koeln, Nordrhein-Westfalen, Germany, 50937
Novartis Investigative Site
Krefeld, Nordrhein-Westfalen, Germany, 47805
Novartis Investigative Site
Leverkusen, Nordrhein-Westfalen, Germany, 51375
Novartis Investigative Site
Minden, Nordrhein-Westfalen, Germany, 32429
Novartis Investigative Site
Moenchengladbach, Nordrhein-Westfalen, Germany, 41061
Novartis Investigative Site
Muelheim, Nordrhein-Westfalen, Germany, 45473
Novartis Investigative Site
Muenster, Nordrhein-Westfalen, Germany, 48149
Novartis Investigative Site
Muenster, Nordrhein-Westfalen, Germany, 48153
Novartis Investigative Site
Olpe, Nordrhein-Westfalen, Germany, 57462
Novartis Investigative Site
Porta Westfalica, Nordrhein-Westfalen, Germany, 32457
Novartis Investigative Site
Solingen, Nordrhein-Westfalen, Germany, 42697
Novartis Investigative Site
Troisdorf, Nordrhein-Westfalen, Germany, 53840
Novartis Investigative Site
Velbert, Nordrhein-Westfalen, Germany, 42551
Novartis Investigative Site
Wesel, Nordrhein-Westfalen, Germany, 46485
Novartis Investigative Site
Witten, Nordrhein-Westfalen, Germany, 58452
Novartis Investigative Site
Wuerselen, Nordrhein-Westfalen, Germany, 52146
Novartis Investigative Site
Wuppertal, Nordrhein-Westfalen, Germany, 42105
Novartis Investigative Site
Wuppertal, Nordrhein-Westfalen, Germany, 42109
Novartis Investigative Site
Wuppertal, Nordrhein-Westfalen, Germany, 42283
Novartis Investigative Site
Ludwigshafen, Rheinland-Pfalz, Germany, 67063
Novartis Investigative Site
Mainz, Rheinland-Pfalz, Germany, 55131
Novartis Investigative Site
Trier, Rheinland-Pfalz, Germany, 54290
Novartis Investigative Site
Homburg/Saar, Saarland, Germany, 66421
Novartis Investigative Site
Landstuhl, Saarland, Germany, 66849
Novartis Investigative Site
Neunkirchen, Saarland, Germany, 66539
Novartis Investigative Site
Saarbruecken, Saarland, Germany, 66113
Novartis Investigative Site
Aschersleben, Sachsen-Anhalt, Germany, 06449
Novartis Investigative Site
Halle, Sachsen-Anhalt, Germany, 06110
Novartis Investigative Site
Halle, Sachsen-Anhalt, Germany, 06120
Novartis Investigative Site
Magdeburg, Sachsen-Anhalt, Germany, 39108
Novartis Investigative Site
Magdeburg, Sachsen-Anhalt, Germany, 39130
Novartis Investigative Site
Stendal, Sachsen-Anhalt, Germany, 39576
Novartis Investigative Site
Weissenfels, Sachsen-Anhalt, Germany, 06667
Novartis Investigative Site
Chemnitz, Sachsen, Germany, 09116
Novartis Investigative Site
Dresden, Sachsen, Germany, 01127
Novartis Investigative Site
Dresden, Sachsen, Germany, 01307
Novartis Investigative Site
Hoyerswerda, Sachsen, Germany, 02977
Novartis Investigative Site
Leipzig, Sachsen, Germany, 04129
Novartis Investigative Site
Leipzig, Sachsen, Germany, 04277
Novartis Investigative Site
Radebeul, Sachsen, Germany, 01445
Novartis Investigative Site
Rodewisch, Sachsen, Germany, 08228
Novartis Investigative Site
Schkeuditz, Sachsen, Germany, 04435
Novartis Investigative Site
Torgau, Sachsen, Germany, 04860
Novartis Investigative Site
Zittau, Sachsen, Germany, 02763
Novartis Investigative Site
Zwickau, Sachsen, Germany, 08060
Novartis Investigative Site
Bad Oldesloe, Schleswig-Holstein, Germany, 23843
Novartis Investigative Site
Flensburg, Schleswig-Holstein, Germany, 24939
Novartis Investigative Site
Geesthacht, Schleswig-Holstein, Germany, 21502
Novartis Investigative Site
Heide, Schleswig-Holstein, Germany, 25746
Novartis Investigative Site
Henstedt-Ulzburg, Schleswig-Holstein, Germany, 24558
Novartis Investigative Site
Itzehoe, Schleswig-Holstein, Germany, 25524
Novartis Investigative Site
Kiel, Schleswig-Holstein, Germany, 24103
Novartis Investigative Site
Kiel, Schleswig-Holstein, Germany, 24105
Novartis Investigative Site
Luebeck, Schleswig-Holstein, Germany, 23538
Novartis Investigative Site
Neumuenster, Schleswig-Holstein, Germany, 24534
Novartis Investigative Site
Rendsburg, Schleswig-Holstein, Germany, 24768
Novartis Investigative Site
Erfurt, Thueringen, Germany, 99085
Novartis Investigative Site
Gera, Thueringen, Germany, 07548
Novartis Investigative Site
Jena, Thueringen, Germany, 07743
Novartis Investigative Site
Meiningen, Thueringen, Germany, 98617
Novartis Investigative Site
Muehlhausen, Thueringen, Germany, 99974
Novartis Investigative Site
Berlin, Germany, 10117
Novartis Investigative Site
Berlin, Germany, 10317
Novartis Investigative Site
Berlin, Germany, 10365
Novartis Investigative Site
Berlin, Germany, 10367
Novartis Investigative Site
Berlin, Germany, 10713
Novartis Investigative Site
Berlin, Germany, 10967
Novartis Investigative Site
Berlin, Germany, 12559
Novartis Investigative Site
Berlin, Germany, 13125
Novartis Investigative Site
Berlin, Germany, 13589
Novartis Investigative Site
Berlin, Germany, 14169
Novartis Investigative Site
Berlin, Germany, 14197
Novartis Investigative Site
Brandenburg, Germany, 14770
Novartis Investigative Site
Bremen, Germany, 28209
Novartis Investigative Site
Bremen, Germany, 28239
Novartis Investigative Site
Friedrichshafen, Germany, 88048
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Hamburg, Germany, 20259
Novartis Investigative Site
Hamburg, Germany, 20357
Novartis Investigative Site
Hamburg, Germany, 22081
Novartis Investigative Site
Hamburg, Germany, 22359
Novartis Investigative Site
Hamburg, Germany, 22457
Novartis Investigative Site
Wuerzburg, Germany, 97080
Greece
Novartis Investigative Site
Athens, Greece, 115 22
Novartis Investigative Site
Athens, Greece, 115 27
Novartis Investigative Site
Athens, Greece, 151 23
Novartis Investigative Site
Athens, Greece, 15123
Novartis Investigative Site
Athens, Greece, 18547
Novartis Investigative Site
Heraklion, Crete, Greece, 71110
Novartis Investigative Site
Patra, Greece, 26504
Novartis Investigative Site
Thessaloniki, Greece, 546 45
Hong Kong
Novartis Investigative Site
Kowloon, Hong Kong
Novartis Investigative Site
Tuen Mun, Hong Kong
Hungary
Novartis Investigative Site
Budapest, Hungary, 1032
Novartis Investigative Site
Budapest, Hungary, 1082
Novartis Investigative Site
Budapest, Hungary, 1122
Novartis Investigative Site
Budapest, Hungary, 1145
Novartis Investigative Site
Győr, Hungary, 9023
Novartis Investigative Site
Szeged, Hungary, 6720
Novartis Investigative Site
Szombathely, Hungary, 9700
India
Novartis Investigative Site
Gurgaon, India, 122002
Novartis Investigative Site
Hyderabad, India, 500082
Novartis Investigative Site
Kolkatta (W.B.), India, 700016
Novartis Investigative Site
Mangalore, India, 575001
Novartis Investigative Site
Mumbai, India, 400012
Novartis Investigative Site
Nagpur, India, 440010
Novartis Investigative Site
New Delhi, India, 110029
Novartis Investigative Site
New Delhi, India, 110076
Novartis Investigative Site
Trivandrum, India, 695011
Ireland
Novartis Investigative Site
Dublin, Ireland, 7
Novartis Investigative Site
Dublin, Ireland, 8
Novartis Investigative Site
Dublin, Ireland, 9
Novartis Investigative Site
Galway, Ireland
Novartis Investigative Site
Limerick, Ireland
Novartis Investigative Site
Sligo, Ireland
Novartis Investigative Site
Tallaght, Dublin, Ireland, 24
Novartis Investigative Site
Wilton, Cork, Ireland
Israel
Novartis Investigative Site
Beer-Sheva, Israel, 84101
Novartis Investigative Site
Haifa, Israel, 31096
Novartis Investigative Site
Holon, Israel, 58100
Novartis Investigative Site
Jerusalem, Israel, 91031
Novartis Investigative Site
Kfar Saba, Israel, 44281
Novartis Investigative Site
Netanya, Israel
Novartis Investigative Site
Ramat Gan, Israel, 52621
Novartis Investigative Site
Rehovot, Israel, 76100
Novartis Investigative Site
Tel Aviv, Israel, 64239
Italy
Novartis Investigative Site
Potenza, Basilicata, Italy, 85100
Novartis Investigative Site
Avellino, Campania, Italy, 83100
Novartis Investigative Site
Carpi (MO), Emilia-Romagna, Italy, 41012
Novartis Investigative Site
Lugo (Ravenna), Emilia-Romagna, Italy, 48022
Novartis Investigative Site
Meldola (FC), Emilia-Romagna, Italy, 47014
Novartis Investigative Site
Ravenna, Emilia-Romagna, Italy, 48121
Novartis Investigative Site
Rimini, Emilia-Romagna, Italy, 47900
Novartis Investigative Site
Aviano (PN), Friuli-Venezia-Giulia, Italy, 33081
Novartis Investigative Site
Udine, Friuli-Venezia-Giulia, Italy, 33100
Novartis Investigative Site
Roma, Lazio, Italy, 00135
Novartis Investigative Site
Roma, Lazio, Italy, 00144
Novartis Investigative Site
Roma, Lazio, Italy, 00168
Novartis Investigative Site
Viterbo, Lazio, Italy, 01100
Novartis Investigative Site
Genova, Liguria, Italy, 16132
Novartis Investigative Site
Alzano Lombardo (BG), Lombardia, Italy, 24022
Novartis Investigative Site
Bergamo, Lombardia, Italy, 24127
Novartis Investigative Site
Brescia, Lombardia, Italy, 25123
Novartis Investigative Site
Brescia, Lombardia, Italy, 25124
Novartis Investigative Site
Cremona, Lombardia, Italy, 26100
Novartis Investigative Site
Lecco, Lombardia, Italy, 23900
Novartis Investigative Site
Mantova, Lombardia, Italy, 46100
Novartis Investigative Site
Milano, Lombardia, Italy, 20141
Novartis Investigative Site
Milano, Lombardia, Italy, 20142
Novartis Investigative Site
Milano, Lombardia, Italy, 20162
Novartis Investigative Site
Monza, Lombardia, Italy, 20052
Novartis Investigative Site
Pavia, Lombardia, Italy, 27100
Novartis Investigative Site
Rozzano (MI), Lombardia, Italy, 20089
Novartis Investigative Site
San Fermo della Battaglia (Co), Lombardia, Italy, 22020
Novartis Investigative Site
Saronno (VA), Lombardia, Italy, 21047
Novartis Investigative Site
Treviglio (BG), Lombardia, Italy, 24047
Novartis Investigative Site
Varese, Lombardia, Italy, 21100
Novartis Investigative Site
Fano (Pesaro Urbino), Marche, Italy, 61032
Novartis Investigative Site
Fermo (AP), Marche, Italy, 63023
Novartis Investigative Site
Asti, Piemonte, Italy, 14100
Novartis Investigative Site
Biella, Piemonte, Italy, 13900
Novartis Investigative Site
Candiolo (TO), Piemonte, Italy, 10060
Novartis Investigative Site
Brindisi, Puglia, Italy, 72100
Novartis Investigative Site
Lecce, Puglia, Italy, 73100
Novartis Investigative Site
Monserrato (CA), Sardegna, Italy, 09042
Novartis Investigative Site
Sassari, Sardegna, Italy, 07100
Novartis Investigative Site
Palermo, Sicilia, Italy, 90127
Novartis Investigative Site
Palermo, Sicilia, Italy, 90146
Novartis Investigative Site
Ragusa, Sicilia, Italy, 97100
Novartis Investigative Site
Firenze, Toscana, Italy, 50134
Novartis Investigative Site
Firenze, Toscana, Italy, 50139
Novartis Investigative Site
Lido di Camaiore (LU), Toscana, Italy, 55043
Novartis Investigative Site
Livorno, Toscana, Italy, 57124
Novartis Investigative Site
Montepulciano (Siena, Toscana, Italy, 53045
Novartis Investigative Site
Pisa, Toscana, Italy, 56126
Novartis Investigative Site
Poggibonsi (Siena), Toscana, Italy, 53036
Novartis Investigative Site
Prato, Toscana, Italy, 59100
Novartis Investigative Site
Trento, Trentino-Alto Adige, Italy, 38122
Novartis Investigative Site
Chieti, Italy, 66100
Novartis Investigative Site
Cosenza, Italy, 87100
Japan
Novartis Investigative Site
Aichi, Japan, 464-8681
Novartis Investigative Site
Chiba, Japan, 277-8577
Novartis Investigative Site
Ehime, Japan, 791-0280
Novartis Investigative Site
Fukuoka, Japan, 811-1395
Novartis Investigative Site
Ibaraki, Japan, 305-8576
Novartis Investigative Site
Kanagawa, Japan, 259-1143
Novartis Investigative Site
Kyoto, Japan, 606-8507
Novartis Investigative Site
Osaka, Japan, 530-8480
Novartis Investigative Site
Osaka, Japan, 540-0006
Novartis Investigative Site
Saitama, Japan, 350-1298
Novartis Investigative Site
Tokyo, Japan, 101-8643
Novartis Investigative Site
Tokyo, Japan, 104-0045
Novartis Investigative Site
Tokyo, Japan, 104-8560
Novartis Investigative Site
Tokyo, Japan, 113-8677
Novartis Investigative Site
Tokyo, Japan, 135-8550
Korea, Republic of
Novartis Investigative Site
Gyeonggi-do, Korea, Republic of, 410-769
Novartis Investigative Site
Incheon, Korea, Republic of, 400-711
Novartis Investigative Site
Seoul, Korea, Republic of, 110-774
Novartis Investigative Site
Seoul, Korea, Republic of, 120-752
Novartis Investigative Site
Seoul, Korea, Republic of, 135-710
Novartis Investigative Site
Seoul, Korea, Republic of, 138-736
Novartis Investigative Site
Suwon, Korea, Republic of, 440-380
Malaysia
Novartis Investigative Site
Kubang Kerian, Malaysia, 16150
Novartis Investigative Site
Sarawak, Malaysia, 93586
Mexico
Novartis Investigative Site
Toluca, Estado de México, Mexico, 50080
Novartis Investigative Site
Merida, Yucatán, Mexico, 97500
Novartis Investigative Site
Chihuahua, Mexico, 31000
Novartis Investigative Site
Mexico City, Mexico, CP 14080
Novartis Investigative Site
Mexico DF, Mexico, 01120
Novartis Investigative Site
México D.F., Mexico, 11000
Netherlands
Novartis Investigative Site
Amersfoort, Netherlands, 3818 ES
Novartis Investigative Site
Amsterdam, Netherlands, 1066 CX
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
Arnhem, Netherlands, 6815 AD
Novartis Investigative Site
Blaricum, Netherlands, 1261 AN
Novartis Investigative Site
Delft, Netherlands, 2625 AD
Novartis Investigative Site
Den Haag, Netherlands, 2512 VA
Novartis Investigative Site
Den Haag, Netherlands, 2545CH
Novartis Investigative Site
Eindhoven, Netherlands, 5623 EJ
Novartis Investigative Site
Gouda, Netherlands, 2803 HH
Novartis Investigative Site
Hoofddorp, Netherlands, 2130 AT
Novartis Investigative Site
Hoogeveen, Netherlands, 7909 AA
Novartis Investigative Site
Leeuwarden, Netherlands, 8934 AD
Novartis Investigative Site
Leiden, Netherlands, 2333 ZA
Novartis Investigative Site
Leidschendam, Netherlands, 2262 BA
Novartis Investigative Site
Purmerend, Netherlands, 1441 RN
Novartis Investigative Site
Rotterdam, Netherlands, 3075 EA
Novartis Investigative Site
Rotterdam, Netherlands, 3083 AN
Novartis Investigative Site
Sittard-geleen, Netherlands, 6162 BG
Novartis Investigative Site
Tilburg, Netherlands, 5022 GC
Novartis Investigative Site
Utrecht, Netherlands, 3582 KE
New Zealand
Novartis Investigative Site
Hamilton, New Zealand, 2001
Novartis Investigative Site
Newtown, Wellington, New Zealand, 6002
Novartis Investigative Site
Palmerston North, New Zealand, 4414
Norway
Novartis Investigative Site
Førde, Norway, 6807
Novartis Investigative Site
Oslo, Norway, 0310
Novartis Investigative Site
Oslo, Norway, 0407
Novartis Investigative Site
Tromsø, Norway, 9038
Pakistan
Novartis Investigative Site
Islamabad, Pakistan, 1590
Novartis Investigative Site
Karachi, Pakistan, 74800
Novartis Investigative Site
Karachi, Pakistan
Novartis Investigative Site
Lahore, Pakistan, 53400
Novartis Investigative Site
Lahore, Pakistan, 54600
Peru
Novartis Investigative Site
Callao, Peru, Callao 2
Novartis Investigative Site
Lima, Peru, Lima 11
Novartis Investigative Site
Lima, Peru, Lima 13
Novartis Investigative Site
Lima, Peru, Lima 34
Philippines
Novartis Investigative Site
Cebu, Philippines, 6000
Novartis Investigative Site
Quezon City, Philippines, 1102
Novartis Investigative Site
Sampaloc Manila, Philippines, 1008
Novartis Investigative Site
San Juan, Philippines, 1502
Poland
Novartis Investigative Site
Bydgoszcz, Poland, 85-796
Novartis Investigative Site
Elblag, Poland, 82-300
Novartis Investigative Site
Gdansk, Poland, 80-211
Novartis Investigative Site
Gdansk, Poland, 80-219
Novartis Investigative Site
Gliwice, Poland, 44-101
Novartis Investigative Site
Krakow, Poland, 31-115
Novartis Investigative Site
Kraków, Poland, 31-108
Novartis Investigative Site
Olsztyn, Poland, 10-226
Novartis Investigative Site
Olsztyn, Poland, 10-228
Novartis Investigative Site
Opole, Poland, 45-060
Novartis Investigative Site
Rzeszow, Poland, 35-055
Novartis Investigative Site
Szczecin, Poland, 71-730
Novartis Investigative Site
Warszawa, Poland, 02-781
Novartis Investigative Site
Wroclaw, Poland, 53-413
Romania
Novartis Investigative Site
Bucharest, Romania, 022328
Novartis Investigative Site
Bucharest, Romania, 050098
Novartis Investigative Site
Bucuresti, Romania, 022328
Novartis Investigative Site
Cluj-Napoca, Romania, 400015
Novartis Investigative Site
Iasi, Romania, 700106
Russian Federation
Novartis Investigative Site
Arkhangelsk, Russian Federation, 163045
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454087
Novartis Investigative Site
Irkutsk, Russian Federation, 664035
Novartis Investigative Site
Kazan, Russian Federation, 420029
Novartis Investigative Site
Kirov, Russian Federation, 610021
Novartis Investigative Site
Moscow, Russian Federation, 115 478
Novartis Investigative Site
Moscow, Russian Federation, 115478
Novartis Investigative Site
Moscow, Russian Federation, 121359
Novartis Investigative Site
Moscow, Russian Federation, 129 128
Novartis Investigative Site
Novosibirsk, Russian Federation, 630047
Novartis Investigative Site
Omsk, Russian Federation, 644013
Novartis Investigative Site
Orenburg, Russian Federation, 460021
Novartis Investigative Site
Ryazan, Russian Federation, 390011
Novartis Investigative Site
Samara, Russian Federation, 443066
Novartis Investigative Site
St. Petersburg, Russian Federation, 197022
Novartis Investigative Site
St. Petersburg, Russian Federation, 197758
Novartis Investigative Site
Voronezh, Russian Federation, 394062
Singapore
Novartis Investigative Site
Singapore, Singapore, 119082
Slovakia
Novartis Investigative Site
Bratislava, Slovakia, 812 50
Novartis Investigative Site
Bratislava, Slovakia, 833 10
Novartis Investigative Site
Kosice, Slovakia, 041 91
Novartis Investigative Site
Poprad, Slovakia, 058 01
Novartis Investigative Site
Rimavska Sobota, Slovakia, 979 01
Novartis Investigative Site
Zilina, Slovakia, 010 01
Slovenia
Novartis Investigative Site
Ljubljana, Slovenia, 1000
South Africa
Novartis Investigative Site
Capital Park, South Africa, 0002
Novartis Investigative Site
Groenkloof, Pretoria, 0001, South Africa, 0081
Novartis Investigative Site
Observatory, South Africa, 7925
Novartis Investigative Site
Panorama, South Africa, 7500
Novartis Investigative Site
Parktown, South Africa, 2193
Novartis Investigative Site
Pretoria, South Africa, 0041
Novartis Investigative Site
Pretoria, South Africa, 0081
Novartis Investigative Site
Sandton, South Africa, 2199
Novartis Investigative Site
Saxonwold, Johannesburg, South Africa, 2196
Spain
Novartis Investigative Site
Alcoy/Alicante, Spain, 03804
Novartis Investigative Site
Barakaldo (Vizcaya), Spain, 48903
Novartis Investigative Site
Barcelona, Spain, 08035
Novartis Investigative Site
Burgos, Spain, 09006
Novartis Investigative Site
Cadiz, Spain, 11009
Novartis Investigative Site
Castellón, Spain, 12002
Novartis Investigative Site
Cordoba, Spain, 14004
Novartis Investigative Site
Coria, Spain, 10800
Novartis Investigative Site
Elda, Spain, 03600
Novartis Investigative Site
Granada, Spain, 18014
Novartis Investigative Site
Hospitalet de Llobregat (Barcelona), Spain, 08907
Novartis Investigative Site
Huesca, Spain, 22300
Novartis Investigative Site
La Laguna (Santa Cruz de Tenerife), Spain, 38320
Novartis Investigative Site
Lerida, Spain, 25198
Novartis Investigative Site
Lugo, Spain, 27003
Novartis Investigative Site
Madrid, Spain, 28006
Novartis Investigative Site
Madrid, Spain, 28007
Novartis Investigative Site
Madrid, Spain, 28033
Novartis Investigative Site
Madrid, Spain, 28034
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Madrid, Spain, 28046
Novartis Investigative Site
Malaga, Spain, 29010
Novartis Investigative Site
Mataro, Spain, 08034
Novartis Investigative Site
Murcia, Spain, 30008
Novartis Investigative Site
Murcia, Spain, 30120
Novartis Investigative Site
Móstoles, Spain, 28935
Novartis Investigative Site
Palma de Mallorca, Spain, 07010
Novartis Investigative Site
Palma de Mallorca, Spain, 07198
Novartis Investigative Site
Pamplona, Spain, 31008
Novartis Investigative Site
Salamanca, Spain, 37007
Novartis Investigative Site
San Sebastián, Spain, 20014
Novartis Investigative Site
Santander, Spain, 39008
Novartis Investigative Site
Santiago, Spain, 15705
Novartis Investigative Site
Segovia, Spain, 40002
Novartis Investigative Site
Sevilla, Spain, 41009
Novartis Investigative Site
Sevilla, Spain, 41014
Novartis Investigative Site
Tarrasa, Barcelona, Spain, 08221
Novartis Investigative Site
Toledo, Spain, 45004
Novartis Investigative Site
Valencia, Spain, 46014
Novartis Investigative Site
Valencia, Spain, 46017
Novartis Investigative Site
Zamora, Spain
Novartis Investigative Site
Zaragoza, Spain, 50009
Switzerland
Novartis Investigative Site
Aarau, Switzerland, 5001
Novartis Investigative Site
Basel, Switzerland, 4031
Novartis Investigative Site
Bellinzona, Switzerland, 6500
Novartis Investigative Site
Bern, Switzerland, 3010
Novartis Investigative Site
Chur, Switzerland, 7000
Novartis Investigative Site
Lausanne, Switzerland, 1005
Novartis Investigative Site
Locarno, Switzerland, 6600
Novartis Investigative Site
St Gallen, Switzerland, 9007
Novartis Investigative Site
Thun, Switzerland, 3600
Novartis Investigative Site
Zuerich, Switzerland, 8091
Novartis Investigative Site
Zürich, Switzerland, 8008
Taiwan
Novartis Investigative Site
Kaohsiung, Taiwan, 807
Novartis Investigative Site
Taichung, Taiwan, 404
Novartis Investigative Site
Tainan County, Taiwan, 736
Novartis Investigative Site
Taipei, Taiwan, 100
Novartis Investigative Site
Taipei, Taiwan, 104
Novartis Investigative Site
Taipei, Taiwan, 105
Novartis Investigative Site
Taipei, Taiwan, 112
Novartis Investigative Site
Taipei, Taiwan, 114
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Bangkok, Thailand, 10400
Novartis Investigative Site
Bangkok, Thailand, 10700
Novartis Investigative Site
Chiangmai, Thailand, 50200
Novartis Investigative Site
Hatyai, Songkhla, Thailand, 90110
Novartis Investigative Site
Khon Kaen, Thailand, 40002
Novartis Investigative Site
Phitsanulok, Thailand, 65000
Ukraine
Novartis Investigative Site
Chernivtsi, Ukraine, 58013
Novartis Investigative Site
Donetsk, Ukraine, 83092
Novartis Investigative Site
Ivano-Frankivsk, Ukraine, 76018
Novartis Investigative Site
Kharkiv, Ukraine, 61024
Novartis Investigative Site
Kyiv, Ukraine, 03115
Novartis Investigative Site
Lviv, Ukraine, 79031
Novartis Investigative Site
Simferopol, Ukraine, 95023
Novartis Investigative Site
Uzhgorod, Ukraine, 88014
Novartis Investigative Site
Uzhorod, Ukraine, 88000
United Kingdom
Novartis Investigative Site
Chelmsford, Essex, United Kingdom, CM1 7ET
Novartis Investigative Site
Epping, Essex, United Kingdom, CM16 6TN
Novartis Investigative Site
Prittlewell Chase, Essex, United Kingdom, SS0 0RY
Novartis Investigative Site
Bristol, Gloucestershire, United Kingdom, BS2 8ED
Novartis Investigative Site
Canterbury, Kent, United Kingdom, CT1 3NG
Novartis Investigative Site
Manchester, Lancashire, United Kingdom, M20 4BX
Novartis Investigative Site
Preston, Lancashire, United Kingdom, PR2 9HT
Novartis Investigative Site
Northwood, Middlesex, United Kingdom, HA6 2RN
Novartis Investigative Site
Edinburgh, Midlothian, United Kingdom, EH4 2XU
Novartis Investigative Site
Headington, Oxford, Oxfordshire, United Kingdom, OX3 7LJ
Novartis Investigative Site
Ashford, United Kingdom, TN24 0LZ
Novartis Investigative Site
Bebington, United Kingdom, CH63 4JY
Novartis Investigative Site
Blackpool, United Kingdom, FY3 8NR
Novartis Investigative Site
Bournemouth, United Kingdom, BH7 7DW
Novartis Investigative Site
Brighton, United Kingdom, BN2 5BE
Novartis Investigative Site
Cardiff, United Kingdom, CF14 2TL
Novartis Investigative Site
Cheltenham, United Kingdom, GL53 7AN
Novartis Investigative Site
Cottingham, United Kingdom, HU16 5JQ
Novartis Investigative Site
Dorchester, United Kingdom, DT1 2JY
Novartis Investigative Site
Exeter, United Kingdom, EX2 5DW
Novartis Investigative Site
Grimsby, United Kingdom, DN33 2BA
Novartis Investigative Site
Guildford, United Kingdom, GU2 7XX
Novartis Investigative Site
Gwynedd, United Kingdom, LL57 2PW
Novartis Investigative Site
Ipswich, United Kingdom, IP4 5PD
Novartis Investigative Site
Lancaster, United Kingdom, LA1 4RP
Novartis Investigative Site
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site
Lindley, huddersfield, United Kingdom, HD3 3EA
Novartis Investigative Site
Liverpool, United Kingdom, L7 8XP
Novartis Investigative Site
London, United Kingdom, EC1A 7BE
Novartis Investigative Site
London, United Kingdom, NW1 2PG
Novartis Investigative Site
London, United Kingdom, NW3 2QG
Novartis Investigative Site
London, United Kingdom, SE1 9RT
Novartis Investigative Site
London, United Kingdom, SW17 0QT
Novartis Investigative Site
London, United Kingdom, SW3 6JJ
Novartis Investigative Site
London, United Kingdom, W2 1NY
Novartis Investigative Site
London, United Kingdom, W6 8RF
Novartis Investigative Site
Maidstone, United Kingdom, ME16 9QQ
Novartis Investigative Site
Margate, United Kingdom, CT9 4AN
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom, NE7 7DN
Novartis Investigative Site
Nottingham, United Kingdom, NG5 1PB
Novartis Investigative Site
Plymouth, United Kingdom, PL6 8DH
Novartis Investigative Site
Poole, Dorset, United Kingdom, BH15 2JB
Novartis Investigative Site
Portsmouth, United Kingdom, PO6 3LY
Novartis Investigative Site
Romford, United Kingdom, RM7 0AG
Novartis Investigative Site
Sheffield, United Kingdom, S10 2SJ
Novartis Investigative Site
Shrewsbury, United Kingdom, SY3 8XQ
Novartis Investigative Site
Southport, United Kingdom, PR8 6PN
Novartis Investigative Site
St Helens, United Kingdom, WA9 3DA
Novartis Investigative Site
Stoke on Trent, United Kingdom, ST4 6QG
Novartis Investigative Site
Sutton, United Kingdom, SM2 5PT
Novartis Investigative Site
Swansea, United Kingdom, SA2 8QA
Novartis Investigative Site
Worthing, United Kingdom, BN11 2DH
Sponsors and Collaborators
Novartis
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Breast International Group
Canadian Cancer Trials Group
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT00490139     History of Changes
Obsolete Identifiers: NCT00609024
Other Study ID Numbers: EGF106708 
Study First Received: June 20, 2007
Results First Received: July 30, 2014
Last Updated: April 3, 2016
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
United States: Food and Drug Administration

Keywords provided by Novartis:
Adjuvant
ErbB2-overexpressing
Early stage breast cancer
HER2/neu gene amplified

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Lapatinib
Trastuzumab
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on December 07, 2016